\r\n\tThe fifth topic is “complications and drug side effects in the treatment of pigmentation disorders”. These include drug allergies, hyper- and hypopigmentation, persistent skin depigmentation, scars, skin burns, and the potential for skin cancer and skin lymphoma. The last topic is called “coping and support along with skin pigmentation diseases”. Increase the quality of life, psychotherapy, team therapy, and asking for understanding and support from family members.
",isbn:"978-1-80356-900-0",printIsbn:"978-1-80356-899-7",pdfIsbn:"978-1-80356-901-7",doi:null,price:0,priceEur:0,priceUsd:0,slug:null,numberOfPages:0,isOpenForSubmission:!1,isSalesforceBook:!1,isNomenclature:!1,hash:"2ac6c9f424eec37ed85232c2c97ef6f6",bookSignature:"Associate Prof. Shahin Aghaei",publishedDate:null,coverURL:"https://cdn.intechopen.com/books/images_new/11698.jpg",keywords:"Melanoma, Post-inflammatory Hyperpigmentation, Albinism, Piebaldism, Vitiligo, Pityriasis Alba, Laser Therapy, Cosmetic Coverage, Drug Reactions, Skin Sensitivity, Quality of Life, Team Therapy",numberOfDownloads:null,numberOfWosCitations:0,numberOfCrossrefCitations:null,numberOfDimensionsCitations:null,numberOfTotalCitations:null,isAvailableForWebshopOrdering:!0,dateEndFirstStepPublish:"April 5th 2022",dateEndSecondStepPublish:"June 14th 2022",dateEndThirdStepPublish:"August 13th 2022",dateEndFourthStepPublish:"November 1st 2022",dateEndFifthStepPublish:"December 31st 2022",dateConfirmationOfParticipation:null,remainingDaysToSecondStep:"2 months",secondStepPassed:!0,areRegistrationsClosed:!0,currentStepOfPublishingProcess:4,editedByType:null,kuFlag:!1,biosketch:"Associate Professor of Clinical Dermatology and Dermatologic Surgery, lead author or contributor to nearly 60 articles published in international dermatology journals, and editor-in-chief of the Journal of Surgical Dermatology in Singapore.",coeditorOneBiosketch:null,coeditorTwoBiosketch:null,coeditorThreeBiosketch:null,coeditorFourBiosketch:null,coeditorFiveBiosketch:null,editors:[{id:"64024",title:"Associate Prof.",name:"Shahin",middleName:null,surname:"Aghaei",slug:"shahin-aghaei",fullName:"Shahin Aghaei",profilePictureURL:"https://mts.intechopen.com/storage/users/64024/images/system/64024.jpg",biography:"Shahin Aghaei, MD, graduated from Shiraz University of Medical Sciences, Iran, in 2004. He was awarded a fellowship from the International Society of Dermatopathology (ISD) from Charles University, Czech Republic, in 2008 and a fellowship in Dermatologic Surgery from the Medical University of Graz, Austria, in 2010. He is currently editor in chief of the Journal of Surgical Dermatology in Singapore and Associate Professor of Dermatology and Dermatologic Surgery at Iran University of Medical Sciences, School of Medicine. He is also a member of the American Academy of Dermatology, European Academy of Dermatology and Venereology, American Society for Laser Medicine and Surgery, International Society of Dermatology, International Hyperhidrosis Society, and Iranian Society of Dermatology.",institutionString:"Iran University of Medical Sciences",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"1",totalChapterViews:"0",totalEditedBooks:"2",institution:{name:"Iran University of Medical Sciences",institutionURL:null,country:{name:"Iran"}}}],coeditorOne:null,coeditorTwo:null,coeditorThree:null,coeditorFour:null,coeditorFive:null,topics:[{id:"16",title:"Medicine",slug:"medicine"}],chapters:null,productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"},personalPublishingAssistant:{id:"225753",firstName:"Marina",lastName:"Dusevic",middleName:null,title:"Ms.",imageUrl:"https://mts.intechopen.com/storage/users/225753/images/7224_n.png",email:"marina.d@intechopen.com",biography:"As an Author Service Manager my responsibilities include monitoring and facilitating all publishing activities for authors and editors. From chapter submission and review, to approval and revision, copyediting and design, until final publication, I work closely with authors and editors to ensure a simple and easy publishing process. I maintain constant and effective communication with authors, editors and reviewers, which allows for a level of personal support that enables contributors to fully commit and concentrate on the chapters they are writing, editing, or reviewing. I assist authors in the preparation of their full chapter submissions and track important deadlines and ensure they are met. I help to coordinate internal processes such as linguistic review, and monitor the technical aspects of the process. As an ASM I am also involved in the acquisition of editors. Whether that be identifying an exceptional author and proposing an editorship collaboration, or contacting researchers who would like the opportunity to work with IntechOpen, I establish and help manage author and editor acquisition and contact."}},relatedBooks:[{type:"book",id:"9076",title:"Recent Advances in Wound Healing",subtitle:null,isOpenForSubmission:!1,hash:"5e10a897612bf74c88669ab634de6459",slug:"recent-advances-in-wound-healing",bookSignature:"Shahin Aghaei",coverURL:"https://cdn.intechopen.com/books/images_new/9076.jpg",editedByType:"Edited by",editors:[{id:"64024",title:"Associate Prof.",name:"Shahin",surname:"Aghaei",slug:"shahin-aghaei",fullName:"Shahin Aghaei"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7045",title:"Tailored Treatments in Psoriatic Patients",subtitle:null,isOpenForSubmission:!1,hash:"47c94f1f1740252164bb2e5ad5c75424",slug:"tailored-treatments-in-psoriatic-patients",bookSignature:"Shahin Aghaei",coverURL:"https://cdn.intechopen.com/books/images_new/7045.jpg",editedByType:"Edited by",editors:[{id:"64024",title:"Associate Prof.",name:"Shahin",surname:"Aghaei",slug:"shahin-aghaei",fullName:"Shahin Aghaei"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"6550",title:"Cohort Studies in Health Sciences",subtitle:null,isOpenForSubmission:!1,hash:"01df5aba4fff1a84b37a2fdafa809660",slug:"cohort-studies-in-health-sciences",bookSignature:"R. Mauricio Barría",coverURL:"https://cdn.intechopen.com/books/images_new/6550.jpg",editedByType:"Edited by",editors:[{id:"88861",title:"Dr.",name:"R. Mauricio",surname:"Barría",slug:"r.-mauricio-barria",fullName:"R. Mauricio Barría"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9500",title:"Recent Advances in Bone Tumours and Osteoarthritis",subtitle:null,isOpenForSubmission:!1,hash:"ea4ec0d6ee01b88e264178886e3210ed",slug:"recent-advances-in-bone-tumours-and-osteoarthritis",bookSignature:"Hiran Amarasekera",coverURL:"https://cdn.intechopen.com/books/images_new/9500.jpg",editedByType:"Edited by",editors:[{id:"67634",title:"Dr.",name:"Hiran",surname:"Amarasekera",slug:"hiran-amarasekera",fullName:"Hiran Amarasekera"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"1591",title:"Infrared Spectroscopy",subtitle:"Materials Science, Engineering and Technology",isOpenForSubmission:!1,hash:"99b4b7b71a8caeb693ed762b40b017f4",slug:"infrared-spectroscopy-materials-science-engineering-and-technology",bookSignature:"Theophile Theophanides",coverURL:"https://cdn.intechopen.com/books/images_new/1591.jpg",editedByType:"Edited by",editors:[{id:"37194",title:"Dr.",name:"Theophile",surname:"Theophanides",slug:"theophile-theophanides",fullName:"Theophile Theophanides"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3161",title:"Frontiers in Guided Wave Optics and Optoelectronics",subtitle:null,isOpenForSubmission:!1,hash:"deb44e9c99f82bbce1083abea743146c",slug:"frontiers-in-guided-wave-optics-and-optoelectronics",bookSignature:"Bishnu Pal",coverURL:"https://cdn.intechopen.com/books/images_new/3161.jpg",editedByType:"Edited by",editors:[{id:"4782",title:"Prof.",name:"Bishnu",surname:"Pal",slug:"bishnu-pal",fullName:"Bishnu Pal"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"371",title:"Abiotic Stress in Plants",subtitle:"Mechanisms and Adaptations",isOpenForSubmission:!1,hash:"588466f487e307619849d72389178a74",slug:"abiotic-stress-in-plants-mechanisms-and-adaptations",bookSignature:"Arun Shanker and B. Venkateswarlu",coverURL:"https://cdn.intechopen.com/books/images_new/371.jpg",editedByType:"Edited by",editors:[{id:"58592",title:"Dr.",name:"Arun",surname:"Shanker",slug:"arun-shanker",fullName:"Arun Shanker"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3092",title:"Anopheles mosquitoes",subtitle:"New insights into malaria vectors",isOpenForSubmission:!1,hash:"c9e622485316d5e296288bf24d2b0d64",slug:"anopheles-mosquitoes-new-insights-into-malaria-vectors",bookSignature:"Sylvie Manguin",coverURL:"https://cdn.intechopen.com/books/images_new/3092.jpg",editedByType:"Edited by",editors:[{id:"50017",title:"Prof.",name:"Sylvie",surname:"Manguin",slug:"sylvie-manguin",fullName:"Sylvie Manguin"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"72",title:"Ionic Liquids",subtitle:"Theory, Properties, New Approaches",isOpenForSubmission:!1,hash:"d94ffa3cfa10505e3b1d676d46fcd3f5",slug:"ionic-liquids-theory-properties-new-approaches",bookSignature:"Alexander Kokorin",coverURL:"https://cdn.intechopen.com/books/images_new/72.jpg",editedByType:"Edited by",editors:[{id:"19816",title:"Prof.",name:"Alexander",surname:"Kokorin",slug:"alexander-kokorin",fullName:"Alexander Kokorin"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"2270",title:"Fourier Transform",subtitle:"Materials Analysis",isOpenForSubmission:!1,hash:"5e094b066da527193e878e160b4772af",slug:"fourier-transform-materials-analysis",bookSignature:"Salih Mohammed Salih",coverURL:"https://cdn.intechopen.com/books/images_new/2270.jpg",editedByType:"Edited by",editors:[{id:"111691",title:"Dr.Ing.",name:"Salih",surname:"Salih",slug:"salih-salih",fullName:"Salih Salih"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}]},chapter:{item:{type:"chapter",id:"15608",title:"Identification of Discharge Coefficients of Orifice-Type Restrictors for Aerostatic Bearings and Application Examples",doi:"10.5772/15830",slug:"identification-of-discharge-coefficients-of-orifice-type-restrictors-for-aerostatic-bearings-and-app",body:null,keywords:null,chapterPDFUrl:"https://cdn.intechopen.com/pdfs/15608.pdf",chapterXML:null,downloadPdfUrl:"/chapter/pdf-download/15608",previewPdfUrl:"/chapter/pdf-preview/15608",totalDownloads:5587,totalViews:117,totalCrossrefCites:0,totalDimensionsCites:3,totalAltmetricsMentions:0,introChapter:null,impactScore:1,impactScorePercentile:56,impactScoreQuartile:3,hasAltmetrics:0,dateSubmitted:"June 17th 2010",dateReviewed:"November 3rd 2010",datePrePublished:null,datePublished:"April 26th 2011",dateFinished:null,readingETA:"0",abstract:null,reviewType:"peer-reviewed",bibtexUrl:"/chapter/bibtex/15608",risUrl:"/chapter/ris/15608",book:{id:"109",slug:"new-tribological-ways"},signatures:"Guido Belforte, Terenziano Raparelli, Andrea Trivella and Vladimir Viktorov",authors:[{id:"14076",title:"Prof.",name:"Guido",middleName:null,surname:"Belforte",fullName:"Guido Belforte",slug:"guido-belforte",email:"guido.belforte@polito.it",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",institution:{name:"Polytechnic University of Turin",institutionURL:null,country:{name:"Italy"}}},{id:"14077",title:"Prof.",name:"Terenziano",middleName:null,surname:"Raparelli",fullName:"Terenziano Raparelli",slug:"terenziano-raparelli",email:"terenziano.raparelli@polito.it",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",institution:{name:"Polytechnic University of Turin",institutionURL:null,country:{name:"Italy"}}},{id:"22013",title:"Dr.",name:"Andrea",middleName:null,surname:"Trivella",fullName:"Andrea Trivella",slug:"andrea-trivella",email:"andrea.trivella@polito.it",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",institution:{name:"Polytechnic University of Turin",institutionURL:null,country:{name:"Italy"}}},{id:"22428",title:"Prof.",name:"Vladimir",middleName:null,surname:"Viktorov",fullName:"Vladimir Viktorov",slug:"vladimir-viktorov",email:"vladimir.viktorov@polito.it",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",institution:{name:"Polytechnic University of Turin",institutionURL:null,country:{name:"Italy"}}}],sections:null,chapterReferences:null,footnotes:null,contributors:null,corrections:null},book:{id:"109",type:"book",title:"New Tribological Ways",subtitle:null,fullTitle:"New Tribological Ways",slug:"new-tribological-ways",publishedDate:"April 26th 2011",bookSignature:"Taher Ghrib",coverURL:"https://cdn.intechopen.com/books/images_new/109.jpg",licenceType:"CC BY-NC-SA 3.0",editedByType:"Edited by",isbn:null,printIsbn:"978-953-307-206-7",pdfIsbn:"978-953-51-6009-0",reviewType:"peer-reviewed",numberOfWosCitations:46,isAvailableForWebshopOrdering:!0,editors:[{id:"21004",title:"Dr.",name:"Taher",middleName:"Hcine",surname:"Ghrib",slug:"taher-ghrib",fullName:"Taher Ghrib"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,coeditorOne:null,coeditorTwo:null,coeditorThree:null,coeditorFour:null,coeditorFive:null,topics:[{id:"813"}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"},chapters:[{id:"15593",type:"chapter",title:"Study of CrAlN Multilayred Thin Films",slug:"study-of-craln-multilayred-thin-films",totalDownloads:3789,totalCrossrefCites:0,signatures:"Tlili Ibrahim and Taher Ghrib",reviewType:"peer-reviewed",authors:[{id:"21004",title:"Dr.",name:"Taher",middleName:"Hcine",surname:"Ghrib",fullName:"Taher Ghrib",slug:"taher-ghrib"}]},{id:"15594",type:"chapter",title:"Optical Characterization of Elastohydrodynamic Lubrication Pressure with Surface Plasmon Resonance",slug:"optical-characterization-of-elastohydrodynamic-lubrication-pressure-with-surface-plasmon-resonance",totalDownloads:2588,totalCrossrefCites:2,signatures:"C.L. Wong, X. Yu, P. Shum and H.P. Ho",reviewType:"peer-reviewed",authors:[{id:"22896",title:"Prof.",name:"Ho-Pui",middleName:null,surname:"Ho",fullName:"Ho-Pui Ho",slug:"ho-pui-ho"},{id:"23339",title:"Dr.",name:"Chi-Lok",middleName:null,surname:"Wong",fullName:"Chi-Lok Wong",slug:"chi-lok-wong"},{id:"28352",title:"Mr.",name:"Xia",middleName:null,surname:"Yu",fullName:"Xia Yu",slug:"xia-yu"},{id:"37307",title:"Prof.",name:"Perry Ping",middleName:null,surname:"Shum",fullName:"Perry Ping Shum",slug:"perry-ping-shum"}]},{id:"15605",type:"chapter",title:"Tribological Properties of Fluorinated Amorphous Carbon Thin Films",slug:"tribological-properties-of-fluorinated-amorphous-carbon-thin-films",totalDownloads:3531,totalCrossrefCites:2,signatures:"Miguel Rubio-Roy, Carles Corbella, José-Luís Andújar, Enric Bertran",reviewType:"peer-reviewed",authors:[{id:"20652",title:"Dr.",name:"Miguel",middleName:null,surname:"Rubio-Roy",fullName:"Miguel Rubio-Roy",slug:"miguel-rubio-roy"},{id:"22834",title:"Dr.",name:"Carles",middleName:null,surname:"Corbella",fullName:"Carles Corbella",slug:"carles-corbella"},{id:"22835",title:"Prof.",name:"Enric",middleName:null,surname:"Bertran",fullName:"Enric Bertran",slug:"enric-bertran"},{id:"38322",title:"Dr.",name:"José-Luís",middleName:null,surname:"Andújar",fullName:"José-Luís Andújar",slug:"jose-luis-andujar"}]},{id:"15610",type:"chapter",title:"Deposition and Tribology of Carbon and Boron Nitride Nanoperiod Multilayer Hard and Solid Lubricating Films",slug:"deposition-and-tribology-of-carbon-and-boron-nitride-nanoperiod-multilayer-hard-and-solid-lubricatin",totalDownloads:2840,totalCrossrefCites:1,signatures:"Shojiro Miyake and Mei Wang",reviewType:"peer-reviewed",authors:[{id:"22097",title:"Dr.",name:"Mei",middleName:null,surname:"Wang",fullName:"Mei Wang",slug:"mei-wang"},{id:"22103",title:"Prof. Dr.",name:"Shojiro",middleName:null,surname:"Miyake",fullName:"Shojiro Miyake",slug:"shojiro-miyake"}]},{id:"15600",type:"chapter",title:"Ferrofluid Seals",slug:"ferrofluid-seals",totalDownloads:3113,totalCrossrefCites:1,signatures:"V. Lemarquand and G. Lemarquand",reviewType:"peer-reviewed",authors:[{id:"12074",title:"Dr.",name:"Guy",middleName:null,surname:"Lemarquand",fullName:"Guy Lemarquand",slug:"guy-lemarquand"},{id:"23316",title:"Prof.",name:"Valerie",middleName:null,surname:"Lemarquand",fullName:"Valerie Lemarquand",slug:"valerie-lemarquand"}]},{id:"15604",type:"chapter",title:"Characteristics of Abrasive Particles and Their Implications on Wear",slug:"characteristics-of-abrasive-particles-and-their-implications-on-wear",totalDownloads:5964,totalCrossrefCites:4,signatures:"Giuseppe Pintaude",reviewType:"peer-reviewed",authors:[{id:"18347",title:"Prof.",name:"Giuseppe",middleName:null,surname:"Pintaude",fullName:"Giuseppe Pintaude",slug:"giuseppe-pintaude"}]},{id:"15599",type:"chapter",title:"Topographical Change of Engineering Surface due to Running-in of Rolling Contacts",slug:"topographical-change-of-engineering-surface-due-to-running-in-of-rolling-contacts",totalDownloads:3499,totalCrossrefCites:3,signatures:"R. Ismail, M. Tauviqirrahman, Jamari and D.J. Schipper",reviewType:"peer-reviewed",authors:[{id:"20733",title:"Mr.",name:"Rifky",middleName:null,surname:"Ismail",fullName:"Rifky Ismail",slug:"rifky-ismail"},{id:"22729",title:"Dr.",name:"Mohammad",middleName:null,surname:"Tauviqirrahman",fullName:"Mohammad Tauviqirrahman",slug:"mohammad-tauviqirrahman"},{id:"22730",title:"Dr.",name:"J",middleName:null,surname:"Jamari",fullName:"J Jamari",slug:"j-jamari"},{id:"22731",title:"Prof.",name:"D.J.",middleName:null,surname:"Schipper",fullName:"D.J. Schipper",slug:"d.j.-schipper"}]},{id:"15606",type:"chapter",title:"Tribology in Water Jet Processes",slug:"tribology-in-water-jet-processes",totalDownloads:6281,totalCrossrefCites:1,signatures:"Seiji Shimizu",reviewType:"peer-reviewed",authors:[{id:"22092",title:"Dr.",name:"Seiji",middleName:null,surname:"Shimizu",fullName:"Seiji Shimizu",slug:"seiji-shimizu"}]},{id:"15590",type:"chapter",title:"The Elliptical Elastic-Plastic Microcontact Analysis",slug:"the-elliptical-elastic-plastic-microcontact-analysis",totalDownloads:2651,totalCrossrefCites:0,signatures:"Jung Ching Chung",reviewType:"peer-reviewed",authors:[{id:"21414",title:"Dr.",name:"Jung-Ching",middleName:null,surname:"Chung",fullName:"Jung-Ching Chung",slug:"jung-ching-chung"}]},{id:"15601",type:"chapter",title:"Methods of Choosing High-Strengthened and Wear-Resistant Steels on a Complex of Mechanical Characteristics",slug:"methods-of-choosing-high-strengthened-and-wear-resistant-steels-on-a-complex-of-mechanical-character",totalDownloads:2334,totalCrossrefCites:0,signatures:"Georgy Sorokin and Vladimir Malyshev",reviewType:"peer-reviewed",authors:[{id:"21979",title:"Dr. Hb., Prof.",name:"Vladimir",middleName:"Nikolaevich",surname:"Malyshev",fullName:"Vladimir Malyshev",slug:"vladimir-malyshev"},{id:"22228",title:"Prof.",name:"Georgy",middleName:null,surname:"Sorokin",fullName:"Georgy Sorokin",slug:"georgy-sorokin"}]},{id:"15612",type:"chapter",title:"A Comparison of the Direct Compression Characteristics of Andrographis paniculata, Eurycoma longifolia Jack, and Orthosiphon stamineus Extracts for Tablet Development",slug:"a-comparison-of-the-direct-compression-characteristics-of-andrographis-paniculata-eurycoma-longifoli",totalDownloads:4137,totalCrossrefCites:1,signatures:"Yus Aniza Yusof, Aziana Azlin Abdul Hamid, So’bah Ahmad, Norawanis Abdul Razak, Chin Nyuk Ling and Suhaila Mohamed",reviewType:"peer-reviewed",authors:[{id:"19376",title:"Dr.",name:"Yus Aniza",middleName:null,surname:"Yusof",fullName:"Yus Aniza Yusof",slug:"yus-aniza-yusof"}]},{id:"15597",type:"chapter",title:"Frictional Property of Flexible Element",slug:"frictional-property-of-flexible-element",totalDownloads:2354,totalCrossrefCites:2,signatures:"Keiji Imado",reviewType:"peer-reviewed",authors:[{id:"18399",title:"Prof.",name:"Keiji",middleName:null,surname:"Imado",fullName:"Keiji Imado",slug:"keiji-imado"}]},{id:"15598",type:"chapter",title:"Surface Friction Properties of Fabrics and Human Skin",slug:"surface-friction-properties-of-fabrics-and-human-skin",totalDownloads:6014,totalCrossrefCites:5,signatures:"Mari Inoue",reviewType:"peer-reviewed",authors:[{id:"18582",title:"Dr.",name:"Mari",middleName:null,surname:"Inoue",fullName:"Mari Inoue",slug:"mari-inoue"}]},{id:"15596",type:"chapter",title:"Investigation of Road Surface Texture Wavelengths",slug:"investigation-of-road-surface-texture-wavelengths",totalDownloads:2997,totalCrossrefCites:1,signatures:"Chengyi Huang and Shunqi Mei",reviewType:"peer-reviewed",authors:[{id:"19772",title:"Dr.",name:"Chengyi",middleName:null,surname:"Huang",fullName:"Chengyi Huang",slug:"chengyi-huang"}]},{id:"15609",type:"chapter",title:"Adhesion Theory for Low Friction on Ice",slug:"adhesion-theory-for-low-friction-on-ice",totalDownloads:3761,totalCrossrefCites:3,signatures:"Katsutoshi Tusima",reviewType:"peer-reviewed",authors:[{id:"19650",title:"Prof.",name:"Katsutoshi",middleName:null,surname:"Tusima",fullName:"Katsutoshi Tusima",slug:"katsutoshi-tusima"}]},{id:"15828",type:"chapter",title:"Tribology of 2-Mercaptobenzothiazole in Lithium Complex Grease",slug:"tribology-of-2-mercaptobenzothiazole-in-lithium-complex-grease",totalDownloads:3322,totalCrossrefCites:0,signatures:"B S Nagarkoti",reviewType:"peer-reviewed",authors:[{id:"21061",title:"Mr.",name:"Bhagwat",middleName:null,surname:"Nagarkoti",fullName:"Bhagwat Nagarkoti",slug:"bhagwat-nagarkoti"}]},{id:"15592",type:"chapter",title:"No Conventional Fluid Film Bearings with Waved Surface",slug:"no-conventional-fluid-film-bearings-with-waved-surface",totalDownloads:1775,totalCrossrefCites:0,signatures:"Florin Dimofte, Nicoleta M. Ene and Abdollah A. Afjeh",reviewType:"peer-reviewed",authors:[{id:"22005",title:"Dr.",name:"Nicoleta",middleName:null,surname:"Ene",fullName:"Nicoleta Ene",slug:"nicoleta-ene"},{id:"22783",title:"Dr.",name:"Florin",middleName:null,surname:"Dimofte",fullName:"Florin Dimofte",slug:"florin-dimofte"}]},{id:"15608",type:"chapter",title:"Identification of Discharge Coefficients of Orifice-Type Restrictors for Aerostatic Bearings and Application Examples",slug:"identification-of-discharge-coefficients-of-orifice-type-restrictors-for-aerostatic-bearings-and-app",totalDownloads:5587,totalCrossrefCites:0,signatures:"Guido Belforte, Terenziano Raparelli, Andrea Trivella and Vladimir Viktorov",reviewType:"peer-reviewed",authors:[{id:"14076",title:"Prof.",name:"Guido",middleName:null,surname:"Belforte",fullName:"Guido Belforte",slug:"guido-belforte"},{id:"14077",title:"Prof.",name:"Terenziano",middleName:null,surname:"Raparelli",fullName:"Terenziano Raparelli",slug:"terenziano-raparelli"},{id:"22013",title:"Dr.",name:"Andrea",middleName:null,surname:"Trivella",fullName:"Andrea Trivella",slug:"andrea-trivella"},{id:"22428",title:"Prof.",name:"Vladimir",middleName:null,surname:"Viktorov",fullName:"Vladimir Viktorov",slug:"vladimir-viktorov"}]},{id:"15595",type:"chapter",title:"Inverse Approach for Calculating Temperature in Thermal Elasto-Hydrodynamic Lubrication of Line Contacts",slug:"inverse-approach-for-calculating-temperature-in-thermal-elasto-hydrodynamic-lubrication-of-line-cont",totalDownloads:2772,totalCrossrefCites:0,signatures:"Li-Ming Chu, Hsiang-Chen Hsu, Jaw-Ren Lin and Yuh-Ping Chang",reviewType:"peer-reviewed",authors:[{id:"9979",title:"Prof.",name:"Hsiang-Chen",middleName:null,surname:"Hsu",fullName:"Hsiang-Chen Hsu",slug:"hsiang-chen-hsu"},{id:"21193",title:"Prof.",name:"Li-Ming",middleName:null,surname:"Chu",fullName:"Li-Ming Chu",slug:"li-ming-chu"},{id:"21194",title:"Prof.",name:"Jaw-Ren",middleName:null,surname:"Lin",fullName:"Jaw-Ren Lin",slug:"jaw-ren-lin"},{id:"21195",title:"Prof.",name:"Yuh-Ping",middleName:null,surname:"Chang",fullName:"Yuh-Ping Chang",slug:"yuh-ping-chang"}]},{id:"15611",type:"chapter",title:"Construction of Various Self-assembled Films and Their Application as Lubricant Coatings",slug:"construction-of-various-self-assembled-films-and-their-application-as-lubricant-coatings",totalDownloads:2354,totalCrossrefCites:0,signatures:"Jinqing Wang, Junfei Ou, Sili Ren and Shengrong Yang",reviewType:"peer-reviewed",authors:[{id:"22526",title:"Prof.",name:"Jinqing",middleName:null,surname:"Wang",fullName:"Jinqing Wang",slug:"jinqing-wang"},{id:"22616",title:"Prof.",name:"Shengrong",middleName:null,surname:"Yang",fullName:"Shengrong Yang",slug:"shengrong-yang"},{id:"27892",title:"Dr.",name:"Junfei",middleName:null,surname:"Ou",fullName:"Junfei Ou",slug:"junfei-ou"},{id:"27893",title:"Prof.",name:"Sili",middleName:null,surname:"Ren",fullName:"Sili Ren",slug:"sili-ren"}]},{id:"15602",type:"chapter",title:"A Novel Tool for Mechanistic Investigation of Boundary Lubrication: Stable Isotopic Tracers",slug:"a-novel-tool-for-mechanistic-investigation-of-boundary-lubrication-stable-isotopic-tracers",totalDownloads:1995,totalCrossrefCites:1,signatures:"Ichiro Minami",reviewType:"peer-reviewed",authors:[{id:"18432",title:"Dr.",name:"Ichiro",middleName:null,surname:"Minami",fullName:"Ichiro Minami",slug:"ichiro-minami"}]},{id:"15607",type:"chapter",title:"FEM Applied to Hydrodynamic Bearing Design",slug:"fem-applied-to-hydrodynamic-bearing-design",totalDownloads:4086,totalCrossrefCites:4,signatures:"Fabrizio Stefani",reviewType:"peer-reviewed",authors:[{id:"20899",title:"Dr.",name:"Fabrizio",middleName:null,surname:"Stefani",fullName:"Fabrizio Stefani",slug:"fabrizio-stefani"}]},{id:"15591",type:"chapter",title:"Comparison between Different Supply Port Configurations in Gas Journal Bearings",slug:"comparison-between-different-supply-port-configurations-in-gas-journal-bearings",totalDownloads:1834,totalCrossrefCites:0,signatures:"Federico Colombo, Terenziano Raparelli and Vladimir Viktorov",reviewType:"peer-reviewed",authors:[{id:"14077",title:"Prof.",name:"Terenziano",middleName:null,surname:"Raparelli",fullName:"Terenziano Raparelli",slug:"terenziano-raparelli"},{id:"22428",title:"Prof.",name:"Vladimir",middleName:null,surname:"Viktorov",fullName:"Vladimir Viktorov",slug:"vladimir-viktorov"},{id:"21110",title:"Dr.",name:"Federico",middleName:null,surname:"Colombo",fullName:"Federico Colombo",slug:"federico-colombo"}]}]},relatedBooks:[{type:"book",id:"6175",title:"Porosity",subtitle:"Process, Technologies and Applications",isOpenForSubmission:!1,hash:"c4cfd280dbc5716589a1062c5a20fcf9",slug:"porosity-process-technologies-and-applications",bookSignature:"Taher Hcine Ghrib",coverURL:"https://cdn.intechopen.com/books/images_new/6175.jpg",editedByType:"Edited by",editors:[{id:"21004",title:"Dr.",name:"Taher",surname:"Ghrib",slug:"taher-ghrib",fullName:"Taher Ghrib"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"},chapters:[{id:"58683",title:"Porous Silicon",slug:"porous-silicon",signatures:"Farshid Karbassian",authors:[{id:"215928",title:"Dr.",name:"Farshid",middleName:null,surname:"Karbassian",fullName:"Farshid Karbassian",slug:"farshid-karbassian"}]},{id:"58429",title:"Nanoporous Carbon Synthesis: An Old Story with Exciting New Chapters",slug:"nanoporous-carbon-synthesis-an-old-story-with-exciting-new-chapters",signatures:"Ana S. Mestre and Ana P. Carvalho",authors:[{id:"214044",title:"Prof.",name:"Ana Paula",middleName:null,surname:"Carvalho",fullName:"Ana Paula Carvalho",slug:"ana-paula-carvalho"},{id:"214045",title:"Dr.",name:"Ana Sofia",middleName:null,surname:"Mestre",fullName:"Ana Sofia Mestre",slug:"ana-sofia-mestre"}]},{id:"58208",title:"Carbon Xerogels: The Bespoke Nanoporous Carbons",slug:"carbon-xerogels-the-bespoke-nanoporous-carbons",signatures:"María Canal-Rodríguez, J. Angel Menéndez and Ana Arenillas",authors:[{id:"14045",title:"Dr.",name:"J. Angel",middleName:null,surname:"Menéndez Díaz",fullName:"J. Angel Menéndez Díaz",slug:"j.-angel-menendez-diaz"},{id:"15134",title:"Dr.",name:"Ana",middleName:null,surname:"Arenillas",fullName:"Ana Arenillas",slug:"ana-arenillas"},{id:"207301",title:"Mrs.",name:"María",middleName:null,surname:"Canal-Rodriguez",fullName:"María Canal-Rodriguez",slug:"maria-canal-rodriguez"}]},{id:"57013",title:"Controlled Porosity in Thermochromic Coatings",slug:"controlled-porosity-in-thermochromic-coatings",signatures:"Ning Wang, Yujie Ke and Yi Long",authors:[{id:"180388",title:"Dr.",name:"Yi",middleName:null,surname:"Long",fullName:"Yi Long",slug:"yi-long"},{id:"218177",title:"Dr.",name:"Ning",middleName:null,surname:"Wang",fullName:"Ning Wang",slug:"ning-wang"},{id:"218178",title:"Mr.",name:"Yujie",middleName:null,surname:"Ke",fullName:"Yujie Ke",slug:"yujie-ke"}]},{id:"58360",title:"Ultrasound Measuring of Porosity in Porous Materials",slug:"ultrasound-measuring-of-porosity-in-porous-materials",signatures:"Zine El Abiddine Fellah, Mohamed Fellah, Claude Depollier, Erick\nOgam and Farid G. Mitri",authors:[{id:"143693",title:"Dr.",name:"Zine El Abiddine",middleName:null,surname:"Fellah",fullName:"Zine El Abiddine Fellah",slug:"zine-el-abiddine-fellah"},{id:"144519",title:"Prof.",name:"Claude",middleName:null,surname:"Depollier",fullName:"Claude Depollier",slug:"claude-depollier"},{id:"178778",title:"Prof.",name:"Mohamed",middleName:null,surname:"Fellah",fullName:"Mohamed Fellah",slug:"mohamed-fellah"},{id:"209074",title:"Dr.",name:"Erick",middleName:null,surname:"Ogam",fullName:"Erick Ogam",slug:"erick-ogam"},{id:"209076",title:"Prof.",name:"F.G.",middleName:null,surname:"Mitri",fullName:"F.G. Mitri",slug:"f.g.-mitri"}]},{id:"59403",title:"Unsteady Magnetohydrodynamic Flow of Jeffrey Fluid through a Porous Oscillating Rectangular Duct",slug:"unsteady-magnetohydrodynamic-flow-of-jeffrey-fluid-through-a-porous-oscillating-rectangular-duct",signatures:"Amir Khan, Gul Zaman and Obaid Algahtani",authors:[{id:"207298",title:"Dr.",name:"Amir",middleName:null,surname:"Khan",fullName:"Amir Khan",slug:"amir-khan"},{id:"218748",title:"Prof.",name:"Gul",middleName:null,surname:"Zaman",fullName:"Gul Zaman",slug:"gul-zaman"},{id:"218749",title:"Prof.",name:"Obaid",middleName:null,surname:"Algehtani",fullName:"Obaid Algehtani",slug:"obaid-algehtani"}]},{id:"57910",title:"Porous Structures in Heat Pipes",slug:"porous-structures-in-heat-pipes",signatures:"Patrik Nemec",authors:[{id:"208635",title:"Ph.D.",name:"Patrik",middleName:null,surname:"Nemec",fullName:"Patrik Nemec",slug:"patrik-nemec"}]},{id:"56922",title:"High-Porosity Metal Foams: Potentials, Applications, and Formulations",slug:"high-porosity-metal-foams-potentials-applications-and-formulations",signatures:"Ahmed Niameh Mehdy Alhusseny, Adel Nasser and Nabeel\nM J Al-zurfi",authors:[{id:"208783",title:"Dr.",name:"Ahmed",middleName:"Niameh Mehdy",surname:"Alhusseny",fullName:"Ahmed Alhusseny",slug:"ahmed-alhusseny"},{id:"208796",title:"Dr.",name:"Adel",middleName:"Gharib",surname:"Nasser",fullName:"Adel Nasser",slug:"adel-nasser"},{id:"217892",title:"Dr.",name:"Nabeel",middleName:null,surname:"Al-Zurfi",fullName:"Nabeel Al-Zurfi",slug:"nabeel-al-zurfi"}]},{id:"58630",title:"Porosity Evolution during Chemo-Mechanical Compaction",slug:"porosity-evolution-during-chemo-mechanical-compaction",signatures:"Anders Nermoen",authors:[{id:"208706",title:"Associate Prof.",name:"Anders",middleName:null,surname:"Nermoen",fullName:"Anders Nermoen",slug:"anders-nermoen"}]},{id:"57224",title:"Role of Interparticle Space in Hollow Spheres of Silica-Based Solid Acids on Their Acidic Properties and Activity for Hydrolytic Dehydrogenation of Ammonia Borane",slug:"role-of-interparticle-space-in-hollow-spheres-of-silica-based-solid-acids-on-their-acidic-properties",signatures:"Tetsuo Umegaki, Toyama Naoki and Yoshiyuki Kojima",authors:[{id:"207629",title:"Dr.",name:"Tetsuo",middleName:null,surname:"Umegaki",fullName:"Tetsuo Umegaki",slug:"tetsuo-umegaki"},{id:"216591",title:"Dr.",name:"Naoki",middleName:null,surname:"Toyama",fullName:"Naoki Toyama",slug:"naoki-toyama"},{id:"216592",title:"Prof.",name:"Yoshiyuki",middleName:null,surname:"Kojima",fullName:"Yoshiyuki Kojima",slug:"yoshiyuki-kojima"}]}]}],publishedBooks:[{type:"book",id:"5226",title:"Fracture Mechanics",subtitle:"Properties, Patterns and Behaviours",isOpenForSubmission:!1,hash:"3d418575458d688abbe40125240ece3e",slug:"fracture-mechanics-properties-patterns-and-behaviours",bookSignature:"Lucas Maximo Alves",coverURL:"https://cdn.intechopen.com/books/images_new/5226.jpg",editedByType:"Edited by",editors:[{id:"147011",title:"Dr.",name:"Lucas",surname:"Alves",slug:"lucas-alves",fullName:"Lucas Alves"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"5495",title:"Lagrangian Mechanics",subtitle:null,isOpenForSubmission:!1,hash:"cd340676a371f5e196f6e8089f5e8b28",slug:"lagrangian-mechanics",bookSignature:"Hüseyin Canbolat",coverURL:"https://cdn.intechopen.com/books/images_new/5495.jpg",editedByType:"Edited by",editors:[{id:"5887",title:"Dr.",name:"Hüseyin",surname:"Canbolat",slug:"huseyin-canbolat",fullName:"Hüseyin Canbolat"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"6228",title:"Vibration Analysis and Control in Mechanical Structures and Wind Energy Conversion Systems",subtitle:null,isOpenForSubmission:!1,hash:"7c08aadadb9857994b1df9abf871c112",slug:"vibration-analysis-and-control-in-mechanical-structures-and-wind-energy-conversion-systems",bookSignature:"Francisco Beltran-Carbajal",coverURL:"https://cdn.intechopen.com/books/images_new/6228.jpg",editedByType:"Edited by",editors:[{id:"10444",title:"Dr.",name:"Francisco",surname:"Beltran-Carbajal",slug:"francisco-beltran-carbajal",fullName:"Francisco Beltran-Carbajal"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"6368",title:"Tribology, Lubricants and Additives",subtitle:null,isOpenForSubmission:!1,hash:"5c3d14346e656a204a188be6e9bbbea1",slug:"lubrication-tribology-lubricants-and-additives",bookSignature:"David W. Johnson",coverURL:"https://cdn.intechopen.com/books/images_new/6368.jpg",editedByType:"Edited by",editors:[{id:"178441",title:"Dr.",name:"David",surname:"Johnson",slug:"david-johnson",fullName:"David Johnson"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7231",title:"Advanced Engineering Testing",subtitle:null,isOpenForSubmission:!1,hash:"9283b3b88964a6fe002fa37431414ac7",slug:"advanced-engineering-testing",bookSignature:"Aidy Ali",coverURL:"https://cdn.intechopen.com/books/images_new/7231.jpg",editedByType:"Edited by",editors:[{id:"13626",title:"Prof.",name:"Aidy",surname:"Ali",slug:"aidy-ali",fullName:"Aidy Ali"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],publishedBooksByAuthor:[{type:"book",id:"493",title:"Pesticides",subtitle:"Formulations, Effects, Fate",isOpenForSubmission:!1,hash:"35f00fd282698d3ff83bd9759c5c7a9c",slug:"pesticides-formulations-effects-fate",bookSignature:"Margarita Stoytcheva",coverURL:"https://cdn.intechopen.com/books/images_new/493.jpg",editedByType:"Edited by",editors:[{id:"6375",title:"Prof.",name:"Margarita",surname:"Stoytcheva",slug:"margarita-stoytcheva",fullName:"Margarita Stoytcheva"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"109",title:"New Tribological Ways",subtitle:null,isOpenForSubmission:!1,hash:"ae099fda1f97a78a3526956c95ec56b6",slug:"new-tribological-ways",bookSignature:"Taher Ghrib",coverURL:"https://cdn.intechopen.com/books/images_new/109.jpg",editedByType:"Edited by",editors:[{id:"21004",title:"Dr.",name:"Taher",surname:"Ghrib",slug:"taher-ghrib",fullName:"Taher Ghrib"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}]},onlineFirst:{chapter:{type:"chapter",id:"82870",title:"Emerging Immunotherapy: Liver Cancer Microenvironment for Treatment",doi:"10.5772/intechopen.106021",slug:"emerging-immunotherapy-liver-cancer-microenvironment-for-treatment",body:'Hepatocellular carcinoma (HCC) is the prevalent primary liver carcinoma and the largest cause of cancer-associated deaths across the globe. HCC accounts for ~90% of cases. Hepatitis B and C virus infections, liver flukes in endemic areas, excessive intake of alcohol, cigarettes, elevated level of body fat, and aflatoxins are all significant risk factors for developing HCC. The tumor burden, liver functioning, comorbidities, and health condition of a patient influence treatment options for HCC. HCC treatments have changed dramatically over the past four decades. Surgical or organ transplantation is the first-line treatment for tumors less than 5 cm in diameter. However, the treatment of large HCCs (those greater than 10 cm) is disputed, with considerable heterogeneity in various treatment regimens in different locations [1]. Additionally, radiofrequency ablation (RFA) and transarterial chemoembolization (TACE) are the local modalities utilized for early and intermediate-stage HCC, accordingly [2, 3]. Systemic treatments for advanced-stage HCC were found controversial prior to 2008 because of their ineffectiveness and poor patient tolerability. Moreover, systemic treatments for liver cancers have made little progress in the last decade.
Immuno-oncology has revolutionized cancer treatment, particularly liver cancer, over the last decade. The antitumor immune response combines innate and adaptive immune system elements [4]. Tumors, on the other hand, can harness this response and use it to evade the immune system in a variety of ways, including maintaining an immunosuppressive milieu or inducing cytotoxic cell malfunctions. An immunosuppressive tumor immune microenvironment (TIME) is marked by the existence of regulatory T cells (Treg), immunosuppressive myeloid cells including tumor-associated macrophages (TAMs), and inhibitory B cells [5]. Immune checkpoint activation, which includes coinhibitory substances, prevents effector cell activation and is crucial for tumor immune evasion [6]. Cancer treatment has been transformed by the development of immune checkpoint inhibitor (ICI)-based therapy, which has led to long-term responses and improved survival in a wide spectrum of cancers. However, ICIs have not been very effective against many solid tumors. Checkpoint proteins expressed by immune cells or tumor cells serve as targets for ICI monoclonal antibodies (mAbs), which elicit a robust immunological response from cytotoxic T lymphocytes (CTLs) [7]. Moreover, ICI therapy has shown to be effective in a subset of patients with a range of cancers, including HCC. Anti-PDL1 antibody atezolizumab and the VEGF neutralizing antibody bevacizumab are now the standard therapies for HCC [8]. Herein, we explored the rationale, molecular basis, and underlying preclinical evidence for immunotherapies in HCC, along with existing immunological clinical research.
The liver is a key immunological organ that receives antigen-rich blood from the gut via the portal vein. Cancer immunosurveillance and control rely heavily on the innate and adaptive immune systems. The conflicting actions of antitumor effectors and their suppressors in the TME determine immune activation or evasion, as shown in (Figure 1). Through highly conserved cytokine and chemokine-activated inflammatory reactions, adaptive and innate immune cells patrol the liver sinusoids to eliminate invading pathogens and endotoxins. The uninflamed liver generates a tolerogenic milieu that suppresses both innate and adaptive immunity in order to maintain homeostasis and prevent chronic inflammation and tissue damage. The immune cell composition of the TME has a huge impact on HCC that can affect tumor initiation, progression, and therapeutic response. During hepatocarcinogenesis, several molecular processes cause distinct immune cell subsets to respond in ways that either cause inflammation or limit antitumor immunity. Herein, the immune cell landscape of HCC is discussed, with an emphasis on the role of innate immune cells and innate-like T cells in HCC, which may lead to the development of candidate immunotherapies that target the underlined cells.
Homeostasis and immune cell composition of the liver.
HCC’s genesis and progression have been linked to inflammation. TNF-α, a key inflammatory mediator, had previously been identified as a possible therapeutic target in a variety of malignancies. Furthermore, TNF-α, interleukin (IL)-1, and IL-6 levels in HCC patients’ serum were found to be considerably greater than in healthy controls. CXCL5 and CCL15, which are produced by tumor cells, attract immunosuppressive neutrophils and monocytes, respectively, while CXCL13, which is produced by hepatic stellate cells, attracts B cells, which differentiate into protumor IgA-producing plasma cells in the context of NASH-associated HCC. IL-2, IFNγ, CXCL10, and CXCL9, on the other hand, recruit lymphocytes to mount an antitumor immune reaction. As a result, the immunological composition and response are determined by the balance of these stimuli. T helper 17 (Th17) cells generate the cytokine IL-17, which has been linked to the development and progression of inflammatory disorders. These findings have ramifications for patients who are undergoing immunotherapy. Activation of the IFN-γ signaling system predicts a favorable response to ICIs, according to the findings of two trials in patients with HCC. In HCC, the tumor microenvironment (TME) has a significant impact on cytokine production.
HCC’s immune microenvironment can be influenced by tumor intrinsic signaling pathways. Wnt ligands produced by HCC cells induce M2 polarization of TAMs, which results in tumor development, metastasis, and immunosuppression in HCC. β-Catenin signaling also inhibits MHC-independent immune responses facilitated by NK cells through decreased expression of NKG2D ligands on HCC cells. By reversing NK cell depletion or TGF- β1 reversing NK cell depletion, blocking the CD96 association restores NK cell immunity to tumors, implying that CD96 may considerably contribute to HCC. MYC may suppress PD-L1 expression in HCC, which suggested that treating HCC with a combination therapy targeting MYC and the PD-L1/PD-1 cascade could be beneficial. HCC is linked to TP53 gene mutations and immune cell heterogeneity, with TP53 mutations reported in roughly 40% of all HCCs. The TP53 mutation-associated immunotype is critical for better clinical outcomes and may have important implications for postoperative tailored follow-up and therapeutic decision-making. Furthermore, ARID1A mutations, which are a common driving factor in HCC, have a considerable contribution to antitumor immunity: they stimulate a positive response by suppressing mismatch repair, leading to an elevated TMB, and also reduce IFNγ signaling by lowering chromatin availability. In co-cultured CD4+ T cells, MDSC suppresses the immune system by generating CD4+ CD25+ Foxp3+ regulatory T cells. The IL6-STAT3-PDL1 signaling cascade is used by HCC-CAFs to control neutrophil survival, stimulation, and function in HCC. Finally, T cell fatigue is caused by the upregulation of immunological checkpoint molecules such as PD-1, PDL1, CTLA4, LAG3, and TIM3 in HCC cells. PDL1 overexpression in Kupffer cells and leukocytes is also caused by prolonged HBV infection, which can boost the protein’s level and enhance immunosuppression in HCCs of this etiology.
HCC is the main cause of death in cirrhotic patients, with HCV or HBV infection accounting for the majority of cases, especially in developing countries. HBV is a hepatotropic virus that causes liver inflammation. While another established risk factor for severe liver disease is HCV, a Flaviviridae virus. Long-term infection with HBV or HCV causes an inflammatory reaction in the liver that can develop into cirrhosis and, ultimately, HCC.
HBV and HCV-induced immune responses might be either procarcinogenic or anticarcinogenic. Platelets generate components that induce a necroinflammatory infiltration,
HCV has a single polyprotein genome, which is translated into structural as well as nonstructural proteins. These HCV proteins are targets for the host’s innate and adaptive immune systems. The principal pattern recognition receptors that identify HCV PAMPs are RIG-I-like receptors and Toll-like receptors. The correlation stimulates a cascade of antiviral cytokines, including interferons. Perforin, as well as granzyme B, is secreted by CD8 + T cells and NK cells while interferon-gamma (IFN-γ) secreted by CD8 + T cells and NK cells causes noncytolytic HCV clearance. Moreover, the host-HCV interactions could make developing an HCV vaccine challenging. It is hard to neutralize a virus that typically has so many mutations in its E1 and E2 proteins, and attempts to do so clear the most abundant variants and leave replicative space for the expansion and continued replication of other quasispecies.
Understanding how virus-related HCCs regulate their metabolism could open up new avenues for immunotherapy. By decreasing arginine, granulocytic MDSCs accumulate in HBV-infected livers and can suppress HBV-specific T cells. High expression of the esterification enzyme sterol Oacyltransferase 1 (SOAT1) disrupts lipid homeostasis, promoting proliferative and migratory potential of the tumor cell in a subset of HBV-associated HCCs while reducing the activity of HBV/HCC-specific tumor-infiltrating lymphocytes.
Hepatic steatosis and chronic necroinflammation in the liver can result from persistent alcohol exposure or high-calorie diets combined with a sedentary lifestyle, leading to HCC, which could be fatal. Moreover, NASH-induced inflammation is more frequently linked with diffuse inflammatory infiltrates.
New developments regarding the cellular and molecular cascades that drive NASH and the NASH-HCC transition have emerged in recent years. It has been revealed that platelets drive NASH and the NASH-HCC transition by fostering the first inflammatory reactions in the context of steatosis. Platelets interact with Kupffer cells and inflammatory monocytes through the platelet-specific glycoprotein Ibα (GPIbα). In rodents, and possibly also in humans, preventive and therapeutic antiplatelet treatment lowers the development of NASH and NASH-associated HCC. The study revealed that the usage of low-dose aspirin is linked with a considerably decreased risk of HCC and liver-associated death. NASH-related liver cancer is caused by a variety of immunological mechanisms. NKT cells mediate lipid uptake via LTβR activation on hepatocytes, and metabolic stimulation of intrahepatic CD8 + T cells and NKT cells, for example, has been demonstrated to induce NASH and HCC via hepatocyte cross talk. NKT cells primarily cause steatosis via secreted LIGHT, while CD8+ and NKT cells cooperatively induce liver damage. The metabolic machinery in hepatocytes is downregulated as a result of this cross talk, which involves direct interaction between immune cells and hepatocytes via Fas and release of porforins and granzymes as well as indirect communication via secreted substances (e.g., cytokines, chemokines), resulting in increased metabolic, endoplasmic reticulum, and mitochondrial stress. Surprisingly, human NASH has been found to have a considerable elevation in the number of intrahepatic CD8 + PD1 + T cells. As previously stated, metabolic imbalance triggers autoaggression in these CD8 + PD1 + T cells, culminating in MHC I independent cytotoxicity against hepatocytes and necroinflammation. This autoaggressive behavior of CD8 + PD1 + T cells has implications for patients receiving ICIs for NASH-associated HCC: nonviral HCCs, particularly NASH-associated HCCs, are less susceptible to these drugs than viral HCCs. This discrepancy has been linked to the autoaggressive intratumoral CD8 + PD1 + T cells losing their tumor surveillance function, resulting in a protumorigenic milieu.
Alcohol consumption is responsible for up to 30% of all HCC cases worldwide. The mucosal damage caused by alcohol might result in an impaired intestinal barrier function, enabling toxins of gut-inhabiting bacteria such as endotoxins to enter the systemic circulation and to contribute to liver injury after alcohol consumption. Alcohol increases gut permeability, allowing immunomodulatory microbiota-derived PAMPs such as LPS to enter the liver and decrease hepatic immune reactions, presumably through effects on resident macrophages. NASH is linked to an increase in protumorigenic, immunosuppressive granulocytic MDSCs in the liver, as well as a decrease in T cell migration to the liver. Furthermore, the neutrophils in the liver parenchyma are a hallmark of alcoholic hepatitis, which is thought to influence the hepatic immune landscape.
Dysbiosis has been seen in various phases of chronic liver injury, including HCC, according to several investigations. The gut microbiota increases HCC development in the setting of chronic liver injury, presumably via microbial metabolites or PAMPs, according to in vivo studies using a mouse model. Through the primary to the secondary conversion of luminal bile acids, the microbiota of the stomach can reduce immunosurveillance and accelerate the progression of HCC. Furthermore, metabolized bile acids (deoxycholic acid, a secondary bile acid) have been demonstrated to cause senescence in hepatic stellate cells, leading to the production of numerous cytokines such as transforming growth factor-β1, angiotensin II, leptin) that enhance the progression of HCC. The relevance of the gut microbiota in influencing systemic immunity, including immunotherapeutic reactions and chemotherapy-induced immunological effects, is now widely recognized. The antigenic epitope tail length tape measure protein 1 (TMP1) in the genome of bacteriophage Enterococcus hirae had high similarity with the proteasome subunit beta type-4 (PSMB4) tumor antigen. They activated CD8+ T cells simultaneously and improved the efficacy of PD-1 blockade therapy. It has been demonstrated that the antigen epitope SVYRYYGL (SVY) expressed in the commensal bacterium Bifidobacterium breve was similar to the tumor-expressed antigen epitope SIYRYYGL (SIY), resulting in SVY-specific T cells recognizing SIY and inhibiting tumor growth. However, further research on the impacts on hepatic immunity is still needed.
Few studies have attempted to classify HCC according to its immunological status. The “Inflammatory” and “Lymphocyte Depleted” clusters were found prominent in HCCs, according to a pancancer analysis based on clustering of immune-associated gene expression profiles. Using a transcriptome deconvolution technique, the first thorough immune categorization of HCC was published in 2017, which found an “Immune” class (which accounts for 25% of HCCs). Immune tumors have an elevated level of immune infiltration, enhanced PD-1/PDL1 signaling, and signature enrichment that mimics the response to ICIs in other solid tumor types.
More recently, a modification of this classification established an “Inflamed” class of HCC, which accounts for about 30–35% of tumors, expanding the previously documented immune class with an additional subset of tumors labeled as an “Immune-like” subclass. This novel subclass is distinguished by the presence of CTNNB1 mutations and significant activation of interferon signaling and immunological activation. T-cell-inflamed tumors are characterized by type I interferon (IFN) activation, immune potentiating chemokines, antigen presentation, cytotoxic effector molecules, and activated CD8+ T cells. The inflamed tumor microenvironment is additionally characterized by IFN-induced inhibitory pathways such as programmed death-ligand 1 (PD-L1) and indoleamine-2, 3 dioxygenase and higher proportions of FOXP3+ regulatory T cells. Patients with HCC have a higher proportion of inflamed tumors, and those patients who responded to anti-PD-1/PDL1 antibodies were shown to be enriched in the inflamed class. In the “Noninflamed” class of HCCs, two subclasses have been evaluated based on the mechanisms of immune escape: (1) an “Intermediate” class with TP53 mutations, elevated levels of chromosomal instability, and frequent deletions in subcytobands harboring genes linked with interferon signaling or antigen presentation; and (2) an “Excluded” class with CTNNB1 mutations and immune desertification features.
Early-stage (BCLC 0 and BCLCA) HCC patients can benefit from treatments such as surgery, liver transplantation, and radiofrequency ablation (RFA) [9]. However, recurrence after liver surgery is prevalent and closely linked to poor overall survival, with recurrence rates of up to 50% and 70% following 2 and 5 years, accordingly [1]. Recurrence is linked to the manifestation of thrombocytopenia, cirrhosis, and satellite lesions [10]. Furthermore, various immunological variables were found with relatively poor resection effects. High PD-L1 expression is linked to an elevated level of immunosuppressive molecules including regulatory T-cells (also known as Tregs) and myeloid-derived suppressor cells (MDSCs) as well as the attenuation of cytotoxic elements such as interferonγ [11, 12, 13, 14]. High CD3+ and CD8+ T cell density in the tumor core and margin, as well as related immune scores, which are based on the number of CD3+ and CD8+ lymphocytes in the intratumor (from the tumor core to the periphery), are linked to a much lower probability of HCC recurrence postsurgical treatment [15, 16]. For patients with unresectable HCC or HCC with end-stage liver disease, liver transplantation is an alternate and possibly ideal therapeutic option. However, only a small percentage of HCC patients match the transplant criteria, and the restricted number of transplant centers makes liver transplantation an unrealistic option for many patients due to the chronic shortage of donor organs. Hence, it is needed to combine adjuvant and neoadjuvant immunotherapy to elevate the likelihood of cure post HCC surgery.
Post resection, numerous adjuvant therapies were undertaken in the hopes of enhancing survival, but none of them was found successful. Systemic treatment has relied heavily on sorafenib over the previous decade, making it the only medicine approved for first-line treatment since 2017. Currently, the approval of lenvatinib has been accepted in the practice of first-line setting [17]. T lymphocytes that have been grown ex vivo with cytokines make up CIK cells. In an open-label, phase-3 trial involving 230 patients (associated with HCC) who experienced surgical resection, patients who got CIK lived 44 months longer than those who received placebo (HR, 0.63; 95% CI 0.43–0.94; p = 0.010). However, despite these recent advancements, no adjuvant therapy has consistently proven effective.
Neoadjuvant therapy is a treatment strategy applied prior to the primary cancer treatment to enhance the rate of success for the primary treatment. In neoadjuvant therapy, ICIs can take advantage of the elevated levels of tumor antigens present in the primary tumor to enhance the proliferative potential of tumor-specific T lymphocyte clones already existing in the TME [18]. Mice administered neoadjuvant Tregs level was reduced due to diphtheria toxin fragments. While anti-CD25 lived considerably longer (250 days) than control mice (100 days) in preclinical models of triple-negative breast cancer [19]. A limited time interval between the first administration of neoadjuvant immunotherapy and primary tumor excision was found essential for maximum efficacy in a second trial, whereas a greater time interval abolished therapeutic efficacy in the neoadjuvant context. The viability of neoadjuvant cabozantinib with nivolumab in HCC was investigated in a single-arm phase 1b study [18]. The trial included 15 unresectable patients, 12 of whom had successful margin-negative resection after neoadjuvant cabozantinib and nivolumab therapy. Furthermore, responders showed enrichment of CD138+ plasma cells and a specific spatial rearrangement of B cells, with B cells in close proximity to other B cells, indicating that this combination modulated the TIME. These findings point to the need for a B-cell orchestration of antitumor immune responses. Immunotherapy is also being researched as a neoadjuvant treatment for liver transplantation. In HCC patients that meet the Milan criteria, the combination of lenvatinib and pembrolizumab is being tested in PLENTY202001 before liver transplantation. The usage of ICIs in the transplant scenario poses considerable safety concerns, as it can result in allograft rejection, which can be deadly [20]. As a result, solid organ patients are routinely excluded from clinical trials employing ICIs. The PLENTY202001 is an outlier in this regard, as it will collect extremely valuable safety data.
TACE is the gold standard of therapy for intermediate-stage BCLC-HCC (B). This immunotherapy significantly improves OS [21]. In addition, TACE seems to influence the immunological response of tumors [22, 23, 24]. TACE can improve both the antitumor immune response and the pro-inflammatory tumor response by lowering Tregs and fatigued effector T-cells in the tumor core [23]. HCC patients (n = 32) who were not eligible for liver surgical resection or transplantation were evaluated for the efficacy and safety of tremelimumab (anti-CTLA-4) with ablation [25]. Tremelimumab was given to patients every 4 weeks for six doses. They had TACE (subtotal radiofrequency ablation) on day 36. Five of the 19 evaluable patients had an established partial response, and the median OS was 19.4 months. Six-week tumor biopsies revealed an increase in CD8+ T cells in those individuals who had a therapeutic benefit. Hence, the combination of locoregional plus immunotherapy for HCC at the intermediate stage is mechanistically justified. Because it enrolled patients with unresectable HCC. Furthermore, The IMbrave 150 trial revealed information regarding HCC-associated patients at an intermediate stage [8]. The ABC-HCC study proposes a novel type of primary endpoint called time-to-failure of treatment strategy, which assesses the time until the investigator discontinues either treatment strategy (systemic therapy or TACE) due to failure [26].
Immunotherapy has been shown to be effective in the treatment of advanced HCC. ICIs, particularly those that target PD-1 or PD-L1, are the most commonly used drugs. They’ve been studied in big clinical studies both individually and in combination, and they have now become an important aspect of HCC treatment. Furthermore, new immunotherapies, including adoptive cell therapy with considerable improvement in ICI’s therapeutic efficacy against HCC.
A monoclonal antibody,
In HCC patients (with a previous history of sorafenib treatment) after intolerable toxicity or rejection of sorafenib, the trial-22 (phase 1/2) found a median OS of 65.6 months (95% CI 7.7–24.6) and a median PFS of 8.69 months (95% CI 1.8–5.4) with an acceptable safety profile for tremelimumab monotherapy. Tremelimumab plus durvalumab (anti-PD-L1), on the other hand, had a better overall benefit–risk ratio [28]. Furthermore, early growth of Ki67+ CD8 + T cells was linked to response to either the single treatment or the combination. This is the final trial that potentially leads to global regulatory clearance for a single drug checkpoint inhibitor. The focus and expectations have shifted to combination therapies in general.
Based on the positive results of the IMbrave150 phase-3 trial 8, the combination of a PD1/PD-L1 inhibitor and a VEGF blocker has become a new strategy to treat advanced HCC [8]. The IMbrave150 experiment resulted in the approval of atezolizumab plus bevacizumab as first-line treatment for unresectable HCC in the United States and Europe, replacing the TKIs sorafenib and lenvatinib. Inhibition of PD-L1, which increases the immune response (especially T-effector cells), and inhibition of VEGF, which stimulates T-cell infiltration in the tumor microenvironment and overcomes VEGF-mediated immunosuppression, is thought to have synergistic antitumor efficacy [29].
The ORIENT-32 phase 2/3 trial compared sintilimab (anti-PD1) and IBI305 (a bevacizumab biosimilar) to sorafenib in systemic treatment-naive Chinese patients, similar to the IMbrave150 trial (NCT03794440). In comparison to sorafenib, sintilimab/IBI305 exhibited an elevated median OS and PFS (median OS: not attained vs. 10.4 months; median PFS: 41.2 weeks vs. 12.17 weeks) with acceptable tolerability of [30].
Immune checkpoint inhibitor therapy for cancer patients has undoubtedly been a big achievement in oncology in recent years, and it represents a huge stride forward as a novel type of immunotherapy in cancer treatment. The combined ICIs including (anti-CTLA-4, and anti-PD-1/L1) are currently being investigated in advanced HCC. The CheckMate 040 trial, which evaluated nivolumab with ipilimumab in 148 patients with advanced HCC who had developed resistance to sorafenib, yielded the first clinical data [31]. The underlined therapy has been approved by the FDA post successful results of the trials. Moreover, systemic steroids are needed to treat adverse events.
Anti-VEGF antibodies can be replaced with ICIs and TKIs to inhibit VEGF. Currently, several such combinations are being investigated. As a secondary outcome measure, cabinozantinib monotherapy is compared with sorafenib. In a phase 1b trial involving 104 patients with unresectable HCC, the combination of lenvatinib with pembrolizumab was found to have potential anticancer efficacy [32].
Finally, camrelizumab (SHR1210, anti-PD-1) and apatinib (rivoceranib, a TKI inhibits VEGFR2) were tested in the clinic. An ORR of 50% was observed in a phase 1 investigation of individuals with advanced HCC [33]. The combination therapies are being evaluated as a first-line treatment for patients with advanced HCC in the phase 3 clinical trial.
The most common method of cancer immunotherapy is the attenuation of the immunological checkpoints PD1/PD-L1 and CTLA-4. LAG-3 is an alternative immunological checkpoint that suppresses T-cell function, indicating T-cell depletion. In phase 2 RELATIVITY-073 trial in advanced, ICI-naive HCC post-progression on prior TKI therapy, relatlimab, an antibody that blocks LAG-3, is being tested in combination with nivolumab. Additionally, a growing number of novel immunotherapeutic methods are being investigated. Where today’s ICIs fail, such interventions could be effective. Adoptive transfer of NK or T cells to increase tumor infiltration, for example, could benefit patients whose tumors aren’t infiltrated by effector immune cells.
Besides classic checkpoint inhibition, the majority of immunotherapies are still in the preclinical or early clinical stages, and these include allogeneic NK cells, CAR-T, as well as oncolytic viruses [34]. CAR-T cells targeting GPC3 are currently being studied in phase 1 trials. Moreover, autologous T cells expressing improved TCRs specific for AFP (AFP c332 T) are being tested in HLA-A2-positive people with advanced HCC in the first phase 1 experiment targeting AFP. Pexastimogene devacirepvec (Pexa-Vec) failed in the TRAVERSE phase 2b trial and the PHOCUS trial as a second-line monotherapy in advanced HCC [35, 36]. Pexa-Vec and nivolumab are currently being tested in a phase 1/2a experiment. Novel immunotherapeutic techniques have the potential to provide immunotherapy benefits to a larger number of patients. However, it is not yet obvious which approaches will enhance or even replace current systemic therapeutic strategies.
In ACT combined with effector cells, lymphocytes are activated and/or amplified ex vivo before being reintroduced into the patients. Redirected peripheral blood T cells, TILs, CIK cells, NK cells, and lymphokine-activated killer cells (LAKs) are among the cell types that are used in this procedure. T-lymphocytes in the peripheral circulation have been genetically recoded to preferentially target tumor cells. The two basic techniques are chimeric antigen receptors (CARs) and transgenic tumor antigen-specific TCRs. CIK, TIL, and LAK therapies are not affected by the cancer-associated genes. Except in LAK, CIK, and CAR T cells, MHC-specific antitumor activity has been found in TIL and TCR-redirected cells. Usually, adoptive transplant cells are preconditioned with fludarabine and cyclophosphamide to promote lymphodepletion and enhance in vivo growth. Patients receiving LAK, CIK, or TIL treatment are often given IL-2 to assist the transferred cells’ proliferation in vivo.
Because of the technology’s apparent complexity and absence of efficiency, the first attempts to use ACT to treat HCC never got to the clinical stage. The fact that LAK cells poorly develop ex-vivo and have a poor cytolytic impact in melanoma patients serves as an example of the intricacy of this system. HCC recurrence was reduced by using LAK cells as an additive following resection to reduce the risk of HCC recurrence. However, this had not improved survival. However, CIK cells are more cytotoxic and proliferative when compared with LAK cells. NKT cells principally contribute to the antitumor effect of this diverse population. In 2015, a multicenter, randomized phase III trial involving 226 patients demonstrated that combination immunotherapy with CIK cells increased PFS and OS of HCC patients following percutaneous ablation or curative surgical resection relative to the patients who did not receive combination therapy. Considering the underlined outcomes, the majority of institutions do not use ACT as adjuvant therapy, most likely due to a lack of in-house cell therapy facilities. From tumor samples (fresh), TILs were obtained followed by selecting the tumor-reactive growing cells on the basis of their autologous cell recognition. Next, these cells were amplified to produce many active cells. The effectiveness of combined TIL treatment was indicated in a Phase-I study with individuals who had HCC7. TILs were given to 15 of 17 patients, with doses up to 3 × 10 [9] cells administered with the least side effects. The major challenges for clinical usage are obtaining sufficient T-cells that are selective for tumor neoepitopes and shortening the underlined procedure.
NK cells have a wide spectrum of receptors that allow them to identify tumor cells even without prior sensitization or the acquisition of receptor reconfiguration. For clinical usage, their inability to grow in vitro may be overcome. Phase II clinical trials are now using allogeneic NK cells to treat patients who have an increased risk of HCC recurrence following surgery or TACE.
In the treatment of hematologic malignancies (such as leukemia, multiple myeloma, and lymphoma), CAR T cell therapy has shown significant promise; however, its use in solid tumors is still under investigation. CAR T cells express transmembrane, intracellular signaling domains, and antigen-recognition domains that are common features of CAR T cells. One-chain variable fragments produced from the variable heavy and light chains of monoclonal antibodies selective for certain tumor cell targets, which can be tumor antigens, usually make up the extracellular antigen-recognition domains. In HCC, GPC3 has emerged as the most specific and appealing target. The efficacy of orthotopic and patient-derived xenografts has been demonstrated in various animal models. One of the most serious issues with CAR T cells is off-target toxicity. This occurs when the expression of the targeting molecule is in non-tumor tissues.
According to several studies, AFP is often overexpressed in HCC. Due to its intracellular expression and secretion, TCR-based therapy is relatively more effective when compared with CAR-based therapies. In patients associated with HCC, four HLA-A2-restricted AFP epitopes were identified. TP53 hotspot mutations, which are common in HCC and HBV antigens, are two more possible targets for T-cells (TCR-engineered).
The key stimulus for using cancer vaccines is to induce tumor-specific reactions with higher efficacy. The underlined impact can be obtained by de novo priming T-cells against antigens produced by tumor cells that do not generate a spontaneous response and further enhancing the remaining reactions or expanding the repertoire and breadth of tumor-specific responses. Vaccinations were once thought to be a stand-alone treatment. However, it is now obvious that they should be used in combination with ICIs or ACT. Combinations of ICIs could block these variables, making it easier for antitumor lymphocytes to accomplish their activities.
In situ therapeutic vaccines act by activating tumor-infiltrating APCs, which absorb and display endogenous TAAs. Classic tumor vaccines, on the other hand, rely on the exogenous delivery of antigens or antigen-pulsed DCs. Cancer antigens should be immunogenic enough to overcome the tolerance induced by multiple self-molecules appearing on tumor cells, while also conferring selectivity for tumor cells and blocking the response of non-tumor cells. Antigen identity is uncertain in tumor lysate, which comprises self-molecules that could not confirm the accurate view of relevant TAA. Using tumor cell lysates as a treatment for HCC in a number of trials did not lead to consistent results.
TAAs including GPC-3, AFP, and telomerase have been addressed as HCC peptide vaccines (antigens specific). HCC patients have revealed spontaneous T-cell responses to the above antigens, suggesting that they are immunogenic in some way. In the majority of cases, T-cell sensitivity to their corresponding antigen is unclear. Hardly a few telomerase and GPC-3-targeting techniques have progressed to clinical evaluations, and none of them has yielded clinically relevant data that could serve as an active pharmaceutical candidate. One of the problems with the approach of therapeutic vaccination is tumor phenotypic heterogeneity and the real possibility that despite best efforts, some tumor cells will simply not be targeted by the vaccine, even if the vaccine is multivalent.
The identification of real tumor-specific antigens should be used to develop more immunogenic vaccinations. HLA peptidomics approaches are the first option that can be used to identify peptides that utilize peptides and serve as a unique immunological signature that CTLs may identify. On the basis of this method, a vaccine clinical evaluation has completed recruitment in HCC.
The use of neoantigens is a second approach. Their detection is based on a complicated pathway that involves analyzing mutations in tumor cells in comparison with wild-type cells. This method is utilized to investigate mutant gene expression as well as immune-associated factors including epitope process ability and HLA molecule interaction. Furthermore, the method has been used to anticipate significantly immunogenic neoantigens with antitumor potential as vaccines in different tumors, including glioblastoma and melanoma. There is a need for extensive studies to clinically evaluate HCC. Only a limited number of studies have been reported that relate the existence of mutations to specific immune responses. According to the results obtained from our ongoing research, mutations observed in HCC patients may generate peptides with stronger HLA-interacting potential when compared with non-mutated wild-type sequences. This research is still being conducted by our group. It has been shown that these peptides stimulate T-cells to recognize only the mutant sequence and not the wild type in HLA-transgenic mice, implying that the method could possibly be used as a vaccination for HCC.
The immune system has developed to deal with microbial infections as well as severe tissue injuries. These situations are recognized by interconnected innate receptors, the function of which determines whether or not an adaptive immune response is produced and progresses. Furthermore, these activities may influence whether tumor antigens trigger immunization, tolerance, or not. As a result, hard efforts have been made over the years in order to develop cancerous tissue that seems like diseased or stressed tissue, which might encourage cytotoxic immunity’s adaptive response. Immune cell death and the use of PAMPs are two important concepts to look into in this context.
Immunogenic cell death (ICD) occurs when cells secrete or synthesize alarmins, a group of proteins that signal and stimulate APCs, i.e., DCs. ICD is linked to ER stress, necroptosis or necrosis, the secretion of mitochondrial and nuclear substances, and the activation of the Type-I IFNs. Moreover, chemo and radiotherapies, as well as other physical stimuli, activate cell and tissue damage and enhance immunity against tumor progression.
The immune system is activated by entities other than viruses, bacteria, and other prokaryotic entities. This reactivity allows drugs such as inflammasome agonists, Toll-like receptor (TLR) agonists, MDA5 or RIGI agonists, and cGAS–STING agonists to be delivered locally, stimulating localized immunity. These substances are usually synthetic analogs or obtained from microbial products, and when administered systemically, cause systemic inflammation and sepsis-like cytokine secretion syndromes. They may be more potent in triggering an immunological response with fewer adverse effects when administered intratumorally. Microorganisms can boost antitumor immunity without using their immune-stimulating substances. Therefore, Bacillus Calmette-Guérin vaccine is used for the local treatment of superficial bladder carcinoma. Oncolytic virotherapy is an effective therapeutic technique against cancer progression. This technique employs viruses that proliferate specifically in cancerous cells in order to kill them, with promising results in HCC. But instead of the cytopathic effects of the viruses, it has become clear that most of the therapeutic benefits of virotherapy come from boosting immune responses that target tumor antigens. Also, spores of anerobic bacteria have been used to amplify immune responses against tumors, since they only germinate in hypoxic environments, which occur in tumor nodules. This is why some bacterial infections trigger immune stimulation that in turn target tumor cells.
Locoregional methods are highly recommended for the treatment of individuals with unresectable HCC. Catheter-based procedures (yttrium-90 irradiation and transarterial chemoembolization) and locoregional ablative treatments, either chemical (percutaneous ethanol injection) or thermal (thermal ablation), are examples of image-guided therapies (laser, microwave, and radiofrequency ablation, and cryoablation) [4]. HCC is favorable for local therapies that can trigger ICD or local delivery of PAMPs due to its easy availability to tumor-affected regions. Notably, multiple locoregional therapies can be used independently or in combination with systemic immunotherapies, to obtain an elevated level of immune activation. Following RFA, immunological responses are activated, and T-cells infiltrate the tumor. In patients with advanced HCC receiving tremelimumab, partial tumor ablation with RFA or TACE achieved a 26% and 89% response rate and disease control rate, respectively. Furthermore, 45% of stabilizations last longer than 26.07 weeks and have an OS of 53.45 weeks [22]. As a result of these encouraging findings, clinical trials involving the use of ICIs, whether alone or combined with other ICIs or bevacizumab, in accordance with chemo, radioembolization, or post-complete percutaneous or surgical ablation, have given considerable support.
It is critical to developing pretreatment baseline levels of T-cell infiltration and stimulation when evaluating response to checkpoint inhibition in different carcinomas. While the influence of CD4+ and CD8 + T-cell infiltration on survival post advanced HCC treatment using second-line PD1 inhibitors has been observed in the form of poor interactions and trends. The underlined results show that the impact is not as significant as originally assumed. According to the immunohistochemistry results, about 20% of advanced HCC tumors express PDL1. Tumor responses were reported in the CheckMate 040 trial independent of PDL1 expression. However, response rates were higher in patients with a minimum of 1% of tumor cells expressing PDL1. PDL1 expression in stromal immune cells as well as in tumor cells was elevated in pembrolizumab-treated patients who obtained objective remission. However, according to the obtained results, the responses were observed even in the absence of expression in both types of cells. In naive patients associated with PDL1-positive HCC, median OS was 70 weeks and 37.3 weeks (HR 0.80), accordingly. In the case of PDL1-negative HCC patients, after sorafenib and nivolumab treatment, the median OS was 72.6 weeks and 66 weeks (HR 0.84), respectively. Furthermore, a trend toward better OS with nivolumab monotherapy was observed in patients with increased tumor infiltration via CD3 + or CD8 + cells. In addition, various signatures of inflammatory genes (such as COX-2) were linked to an elevated response rate and OS. The underlined gene signatures were linked to inflammatory activities, cytolytic genes, IFN-associated genes, exhaustion markers, NK cell markers, and antigen presentation. In this view, these findings reveal an elevated level and activity of T cells and NK cells that utilize cytolysis and IFNγ as their primary antitumor effector mechanisms. In this study, the most complicated transcriptome classification, which includes a huge set of genes, was not found to be predictive of response. However, in the current evaluation, the number of patients for whom small data of RNA sequencing were existing, as large sample data could provide more definitive outcomes (positive or negative). Integrating genomics and transcriptomics into immunotherapy effectiveness will include comprehensive integrative analysis as well as obtaining biopsy samples before and during therapy.
Patients with objective remissions demonstrated potent CD3 + and CD8 + infiltration as compared with non-responders in paired HCC biopsy samples taken prior to and post two doses of tremelimumab. In the case of the combinations, objective HCC remissions were achieved regardless of PDL1 expression in nivolumab + ipilimumab treated cancerous cells. A single biomarker is insufficiently sensitive to provide timely clinical data. However, thorough immunohistological, mutational, and transcriptomic evaluations are required, as integrated multifactorial indices may be able to determine subgroups of individuals who would take advantage of ICI treatment. The significance of matching biopsies prior to and following treatment cannot be emphasized, since diagnostic biopsies for HCC are rarely taken.
The question of whether we are dealing with synergistic effects or just an additive impact arises when evaluating the enhanced combination of ICI therapeutic efficacy. Complementary analysis from major clinical studies is still lacking. Nevertheless, a subgroup analysis has reported a correlation between durvalumab, tremelimumab, or both in combinations. Furthermore, on day 15 after therapy began, an elevated level of proliferating Ki67 + CD8 + T cells among blood mononuclear cells was observed. In particular, in comparison with durvalumab, tremelimumab monotherapies, or the combined effect of a routine low dosage of tremelimumab with a similar dosage of durvalumab, the elevation in the underlined population of peripheral effector T-cells was found optimum for responders to an elevated priming dosage of durvalumab plus tremelimumab. The underlined combined therapies obtained the highest OS. It could be helpful to use biomarkers that are easily available to help design new combinations of therapies and to compare data between combinations. Significant TME changes were found in animal models with VEGFR blockade. The blockage of VEGFR improves PD1 inhibitory activity. According to multiple reported studies on mouse models, combined VEGFR and PD1 inhibition decreases M2-polarized macrophages and T-reg cells, enhances HCC cells and PDL1 expression in TAMs, and enhances normalized vasculature development triggered by CD4 + cells. Notably, effectiveness was achieved with a low dosage of anti-angiogenics (vascular normalizing rather than anti-vascular), offering a promising path of research into minimizing the associated toxicities.
The development of ADAs (anti-drug antibodies) that can affect the elimination of these drugs or neutralize their effectiveness is another viable cause of tumor resistance. The estimated prevalence of ADAs during monotherapies with anti-CTLA4 (ipilimumab), anti-PD1 (cemiplimab, nivolumab, and pembrolizumab), and anti-PDL1 (durvalumab and avelumab) agents is low, ranging from 0 to 12.7% in all tumor types. While no relevant impact of ADAs on efficiency has been noticed for nivoluma. ADAs, on the other hand, were found in up to 36% of NSCLC patients who had received atezolizumab and had a negative impact on systemic exposure to the drug as well as antitumor effectiveness. In the case of HCC, effectiveness (impact on OS) was poorer in the 20% of patients (ADA-positive by week 6) treated with bevacizumab and atezolizumab in a subanalysis of the IMbrave150 study. PD-L1 and CTLA4 are only two molecules that are involved in T cell exhaustion. There are many others on the surface of tumor cells that could compensate. Also, CTLs may have a hard time penetrating solid tumors, especially those that are encased in a fibrous capsule. This may also limit the effects of immunotherapy.
Immune checkpoints or coinhibitory receptors including CTLA-4 and PD-1 control T cell reactions and are efficient therapeutic targets [37, 38]. One of the drawbacks of the underlined advancements in the development of a novel spectrum of immune-related adverse events (irAEs), which are frequently distinct from the conventional toxicities associated with chemotherapy. Due to the rising use of ICIs in oncology, clinicians will progressively encounter both frequent and rare irAEs; hence, it is needed to increase attention regarding the clinical manifestation, evaluation, and managing these toxicities.
Unlike anti-CTLA-4-related adverse events, the risk of irAEs caused by PD-1/PD-L1 inhibition is independent of dosage [39, 40]. The skin and gastrointestinal tract were the most commonly affected organ systems by anti-CTLA4 and PD-1/PD-L1 inhibitors, whereas the liver and the endocrine system were less frequently damaged [39, 40]. However, ipilimumab was found to be linked with a considerably elevated incidence of rash and colitis than anti-PD-1/PD-L1 medicines [41].
Since irAEs are linked with a large array of aggravating conditions in the HCC, hepatologists face numerous hurdles while detecting and treating them. First, liver cirrhosis causes immunological dysfunction, which worsens over time [42]. Consequently, the immunological homeostasis linked with the liver in these patients is substantially damaged. Second, cirrhosis-related hepatic and extrahepatic consequences may overlap with or intensify symptoms mediated by irAEs [43]. Consequently, prior to ICI therapy, HCC patients should be carefully selected and evaluated [43].
Furthermore, the underlined approaches should be utilized for managing irAEs. First, strict surveillance is required, with weekly clinical controls, based on the intensity of the incidents. This is especially critical in patients with liver cirrhosis because distinguishing between problems (linked with cirrhosis) and irAEs can be difficult, and prematurely terminating a considerable antitumor therapy or initiating steroid therapy in cirrhotic patients might have serious implications [43].
Depending on the nature and severity of irAEs, it may be required to temporarily stop or permanently discontinue ICI therapy. With the exception of PD-1/PD-L1-driven rash, nephritis, adrenal insufficiency, and hypothyroidism, which recover after 1 month of treatment, permanent termination of ICI therapy should be addressed for irAEs of grade ≥ 3 [43]. There is a considerable risk of recurrence of irAEs when ICI medication is restarted after it has been discontinued: Twenty-five percent (22 of 40) of the 93 patients with irAEs of grade ≥ 2 who were treated with anti-PD-1/PD-L1 drugs had a recurrence of irAEs post-termination [44]. While recurrence of irAEs was linked with a more rapid onset of the early irAE, the frequency of the recurring irAEs did not vary [44]. TKIs used for HCC include sorafenib, lenvatinib, regorafenib and cabozantinib, all of which are associated with skin toxicity. However, the type of adverse effect and time course can help distinguish between ICI- and TKI-related events. For TKIs, the onset of rash is usually within weeks of starting and palmar-plantar erythema is the most common AE, reported in 52% and 27% of patients receiving sorafenib and lenvatinib, respectively. 29 This compares with around 2% for PD1 inhibitors. Additionally, the relatively short half-life of TKIs results in rapid resolution of skin toxicity over the course of days, which contrasts with the weeks or months that may be required for ICI-related toxicity to resolve.
Glucocorticoids may be prescribed for irAEs of grade ≥ 2 (0.5–2 mg/kg/day prednisone PO or IV, depending on the kind and intensity of the irAEs). Topical, oral, and intravenous glucocorticoids, as well as oral or topical antihistamines, are used to treat cutaneous irAEs, which range from simple rash or itch to less common but more serious illnesses such as Stevens-Johnson syndrome (SJS) [43]. Stevens-Johnson syndrome (SJS) is a form of severe adverse drug reactions and is characterized by epidermal necrolysis. The disease has the unique expression of blisters on the skin and the affection of mucous membranes in the mouth, nose, eyes, and genitals. SJS is characterized by a large area of skin and mucosal epithelial cell shedding and typical performance on the oropharynx, eyes, urogenitals, and anal mucosa. SJS has less than 10% of body surface area involvement. Steroids should be continued for at least 3 days before being reduced over 1–4 weeks [21, 45]. It should be noted that steroids are only beneficial in non-viral-associated chronic liver disease. If viruses are involved (HBV, HCV), steroids will simply permit virus replication to increase, and when steroids are withdrawn, a severe exacerbation of chronic liver disease may be seen.
Differential diagnosis is required for gastrointestinal irAEs, notably colitis and/or diarrhea, to rule out infectious illnesses and medication adverse effects [43]. For grades 2 and ≥ 3, glucocorticoids should be started, and hospitalization with sigmoidoscopy/colonoscopy should be considered. Moreover, immunosuppressive medication should be added early in the case of glucocorticoid failure [43, 46]. Depending on the steroid reaction and the severity of clinical presentation, discontinuation should be done over 2–8 weeks [21, 45].
Immune-related hepatitis is particularly difficult to diagnose and treat in individuals with HCC who are receiving ICI therapy [43]. However, early contact with an experienced hepatologist is thus strongly advised. Intrahepatic growth of the tumor, HBV/HCV flares, and adverse events linked with hepatotoxic medication, ascites, cholestasis, and CMV reactivation should all be ruled out before a diagnosis of immune-associated hepatitis is made. A liver biopsy should also be conducted prior to the administration of steroids [43].
Pneumonitis is an irAE that can be life-threatening. Hence, a prompt and extensive differential diagnosis should be conducted with suspected pneumonitis, including the exclusion of portopulmonary hypertension, viral etiologies, and hepatopulmonary syndrome [43]. Steroids should be started for grade 2 and discontinued over a period of 4–6 weeks [21]. Post glucocorticoid failure, infliximab (which is inflammatory by inhibiting TNFα) or mycophenolate mofetil (an immunosuppressive compound that inhibits inosine monophosphate dehydrogenase) may be administered [43]. It should be noted that therapeutic approaches involving prolonged immunosuppression increase the risk for selected infectious diseases and tumor types that usually never develop in the presence of intact immune surveillance.
The licensing of the initial ICIs in advanced HCC and their clinical efficacy have revolutionized the concept of cancer immunotherapy. However, this field still has to address three major questions: Is immunotherapy beneficial in the preclinical stage? If so, it will reduce the risk of disease progression to cancer. In addition to PD-1/PD-L1/CTLA-4 suppression, which immunological treatments have antitumor effects in HCC? Which therapy options exist for patients not responding to the presently approved ICIs? Perhaps immunomodulation with histone deacetylase inhibitors (HDACi) in combination with ICI would permit a sustained antitumor response with reduced risk of adverse effects.
In response to the first question, various clinical studies in the initial and intermediate stages have reported the use of ICIs. It’s uncertain whether checkpoint inhibitor exhibit regimens are a TACE alternative. As an alternative, the RENOTACE and ABC-HCC trials will test atezolizumab with bevacizumab and regorafenib plus nivolumab. Patients above the up-to-seven criteria, i.e., the subgroup with a relatively great tumor burden at an advanced stage, were recruited for RENOTACE, whereas patients with the whole spectrum of intermediate stages of disease were targeted for ABC-HCC. In addition, the initial trials examining ICIs for neoadjuvant approaches are currently in progress. The underlined collection of trials will look at the safety and efficacy of immunotherapy in the initial and intermediate stages from a variety of perspectives, providing high-quality data that will be useful in understanding the contribution of ICIs in the underlined situations.
To address the second question, there are a number of treatments that are currently being evaluated in clinical trials, which include the use of oncolytic viruses, CAR T/NK cells, and LAG-3 checkpoint inhibitors. These treatments might help patients with established ICIs who are unresponsive or have failed to respond to the treatment.
The third question may also be addressed by the above new immunotherapeutic strategies. A subset of patients, particularly those with an immunological desert TME, is likely to take advantage less of immunotherapy. Although immunotherapy has made tremendous advances. It should not be overlooked when considering treatment options for patients who may benefit from existing and future specialized therapies.
This manuscript is supported by Natural Science Foundation of Shandong Province (ZR2021MH022).
No competing interests exist among the authors.
Based on the outcomes of recent clinical trials, it appears that a single agent may not be sufficient for treating HCC; consequently, combination therapy characterizes an important area of research for the systemic treatment of advanced HCC. Moreover, ICIs are now being considered as part of HCC treatments, and their use in combination with molecular targeted therapy is shown to be an effective way to boost the immune system’s response. The combined therapy of atezolizumab/bevacizumab is the first-line treatment to receive regulatory approval.
Immune checkpoint inhibitors (ICIs) may potentially be effective at earlier stages of illness. Combination therapies are being investigated in the intermediate stage in combination with or in place of transarterial chemotherapy, which is currently the standard of care. ICIs are also being explored as adjuvant and neoadjuvant therapy in the setting of early and very early surgery or ablation.
New research reveals that the control of the commensal gut microbiome and hepatic antitumor immunity are linked. Moreover, ICIs have been linked to immune-related side effects. In HCC clinical studies, however, the prevalence of grade 3/4 incidents was moderate. Therefore, ICIs are largely considered to be a choice in advanced HCC patients.
If your research is financed through any of the below-mentioned funders, please consult their Open Access policies or grant ‘terms and conditions’ to explore ways to cover your publication costs (also accessible by clicking on the link in their title).
\n\nIMPORTANT: You must be a member or grantee of the listed funders in order to apply for their Open Access publication funds. Do not attempt to contact the funders if this is not the case.
",metaTitle:"List of Funders by Country",metaDescription:"If your research is financed through any of the below-mentioned funders, please consult their Open Access policies or grant ‘terms and conditions’ to explore ways to cover your publication costs (also accessible by clicking on the link in their title).",metaKeywords:null,canonicalURL:"/page/open-access-funding-funders-list",contentRaw:'[{"type":"htmlEditorComponent","content":"Book Chapters and Monographs
\\n\\nMonographs Only
\\n\\nBook Chapters and Monographs
\\n\\n\\n\\nBook Chapters and Monographs
\\n\\nBook Chapters and Monographs
\\n\\nBook Chapters and Monographs
\\n\\nBook Chapters and Monographs
\\n\\nBook Chapters and Monographs
\\n\\nBook Chapters and Monographs
\\n\\nBook Chapters and Monographs
\\n\\nMonographs Only
\\n\\nLITHUANIA
\\n\\nBook Chapters and Monographs
\\n\\n\\n\\nBook Chapters and Monographs
\\n\\n\\n\\nBook Chapters and Monographs
\\n\\n\\n\\nSWITZERLAND
\\n\\nBook Chapters and Monographs
\\n\\nBook Chapters and Monographs
\\n\\n\\n\\nBook Chapters and Monographs
\\n\\nBook Chapters and Monographs
\n\nMonographs Only
\n\nBook Chapters and Monographs
\n\n\n\nBook Chapters and Monographs
\n\n\n\nBook Chapters and Monographs
\n\nBook Chapters and Monographs
\n\nBook Chapters and Monographs
\n\nBook Chapters and Monographs
\n\n\n\nBook Chapters and Monographs
\n\nBook Chapters and Monographs
\n\n\n\nMonographs Only
\n\n\n\nLITHUANIA
\n\nBook Chapters and Monographs
\n\n\n\nBook Chapters and Monographs
\n\n\n\nBook Chapters and Monographs
\n\n\n\nSWITZERLAND
\n\nBook Chapters and Monographs
\n\n\n\nBook Chapters and Monographs
\n\n\n\nBook Chapters and Monographs
\n\n\r\n\tThis book series will offer a comprehensive overview of recent research trends as well as clinical applications within different specialties of dentistry. Topics will include overviews of the health of the oral cavity, from prevention and care to different treatments for the rehabilitation of problems that may affect the organs and/or tissues present. The different areas of dentistry will be explored, with the aim of disseminating knowledge and providing readers with new tools for the comprehensive treatment of their patients with greater safety and with current techniques. Ongoing issues, recent advances, and future diagnostic approaches and therapeutic strategies will also be discussed. This series of books will focus on various aspects of the properties and results obtained by the various treatments available, whether preventive or curative.
",coverUrl:"https://cdn.intechopen.com/series/covers/3.jpg",latestPublicationDate:"August 14th, 2022",hasOnlineFirst:!0,numberOfPublishedBooks:9,editor:{id:"419588",title:"Ph.D.",name:"Sergio",middleName:"Alexandre",surname:"Gehrke",slug:"sergio-gehrke",fullName:"Sergio Gehrke",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0033Y000038WgMKQA0/Profile_Picture_2022-06-02T11:44:20.jpg",biography:"Dr. Sergio Alexandre Gehrke is a doctorate holder in two fields. The first is a Ph.D. in Cellular and Molecular Biology from the Pontificia Catholic University, Porto Alegre, Brazil, in 2010 and the other is an International Ph.D. in Bioengineering from the Universidad Miguel Hernandez, Elche/Alicante, Spain, obtained in 2020. In 2018, he completed a postdoctoral fellowship in Materials Engineering in the NUCLEMAT of the Pontificia Catholic University, Porto Alegre, Brazil. He is currently the Director of the Postgraduate Program in Implantology of the Bioface/UCAM/PgO (Montevideo, Uruguay), Director of the Cathedra of Biotechnology of the Catholic University of Murcia (Murcia, Spain), an Extraordinary Full Professor of the Catholic University of Murcia (Murcia, Spain) as well as the Director of the private center of research Biotecnos – Technology and Science (Montevideo, Uruguay). Applied biomaterials, cellular and molecular biology, and dental implants are among his research interests. He has published several original papers in renowned journals. In addition, he is also a Collaborating Professor in several Postgraduate programs at different universities all over the world.",institutionString:null,institution:{name:"Universidad Católica San Antonio de Murcia",institutionURL:null,country:{name:"Spain"}}},editorTwo:null,editorThree:null},subseries:{paginationCount:2,paginationItems:[{id:"1",title:"Oral Health",coverUrl:"https://cdn.intechopen.com/series_topics/covers/1.jpg",isOpenForSubmission:!0,annualVolume:11397,editor:{id:"173955",title:"Prof.",name:"Sandra",middleName:null,surname:"Marinho",slug:"sandra-marinho",fullName:"Sandra Marinho",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002bRGYMQA4/Profile_Picture_2022-06-01T13:22:41.png",biography:"Dr. Sandra A. Marinho is an Associate Professor and Brazilian researcher at the State University of Paraíba (Universidade Estadual da Paraíba- UEPB), Campus VIII, located in Araruna, state of Paraíba since 2011. She holds a degree in Dentistry from the Federal University of Alfenas (UNIFAL), while her specialization and professional improvement in Stomatology took place at Hospital Heliopolis (São Paulo, SP). Her qualifications are: a specialist in Dental Imaging and Radiology, Master in Dentistry (Periodontics) from the University of São Paulo (FORP-USP, Ribeirão Preto, SP), and Doctor (Ph.D.) in Dentistry (Stomatology Clinic) from Hospital São Lucas of the Pontifical Catholic University of Rio Grande do Sul (HSL-PUCRS, Porto Alegre, RS). She held a postdoctoral internship at the Federal University from Jequitinhonha and Mucuri Valleys (UFVJM, Diamantina, MG). She is currently a member of the Brazilian Society for Dental Research (SBPqO) and the Brazilian Society of Stomatology and Pathology (SOBEP). Dr. Marinho's experience in Dentistry mainly covers the following subjects: oral diagnosis, oral radiology; oral medicine; lesions and oral infections; oral pathology, laser therapy and epidemiological studies.",institutionString:null,institution:{name:"State University of Paraíba",institutionURL:null,country:{name:"Brazil"}}},editorTwo:null,editorThree:null},{id:"2",title:"Prosthodontics and Implant Dentistry",coverUrl:"https://cdn.intechopen.com/series_topics/covers/2.jpg",isOpenForSubmission:!0,annualVolume:11398,editor:{id:"179568",title:"Associate Prof.",name:"Wen Lin",middleName:null,surname:"Chai",slug:"wen-lin-chai",fullName:"Wen Lin Chai",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002bRHGAQA4/Profile_Picture_2022-05-23T14:31:12.png",biography:"Professor Dr. Chai Wen Lin is currently a lecturer at the Department of Restorative Dentistry, Faculty of Dentistry of the University of Malaya. She obtained a Master of Dental Science in 2006 and a Ph.D. in 2011. Her Ph.D. research work on the soft tissue-implant interface at the University of Sheffield has yielded several important publications in the key implant journals. She was awarded an Excellent Exchange Award by the University of Sheffield which gave her the opportunity to work at the famous Faculty of Dentistry of the University of Gothenburg, Sweden, under the tutelage of Prof. Peter Thomsen. In 2016, she was appointed as a visiting scholar at UCLA, USA, with attachment in Hospital Dentistry, and involvement in research work related to zirconia implant. In 2016, her contribution to dentistry was recognized by the Royal College of Surgeon of Edinburgh with her being awarded a Fellowship in Dental Surgery. She has authored numerous papers published both in local and international journals. She was the Editor of the Malaysian Dental Journal for several years. Her main research interests are implant-soft tissue interface, zirconia implant, photofunctionalization, 3D-oral mucosal model and pulpal regeneration.",institutionString:null,institution:{name:"University of Malaya",institutionURL:null,country:{name:"Malaysia"}}},editorTwo:{id:"479686",title:"Dr.",name:"Ghee Seong",middleName:null,surname:"Lim",slug:"ghee-seong-lim",fullName:"Ghee Seong Lim",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0033Y00003ScjLZQAZ/Profile_Picture_2022-06-08T14:17:06.png",biography:"Assoc. Prof Dr. Lim Ghee Seong graduated with a Bachelor of Dental Surgery from University of Malaya, Kuala Lumpur in 2008. He then pursued his Master in Clinical Dentistry, specializing in Restorative Dentistry at Newcastle University, Newcastle, UK, where he graduated with distinction. He has also been awarded the International Training Fellowship (Restorative Dentistry) from the Royal College of Surgeons. His passion for teaching then led him to join the faculty of dentistry at University Malaya and he has since became a valuable lecturer and clinical specialist in the Department of Restorative Dentistry. He is currently the removable prosthodontic undergraduate year 3 coordinator, head of the undergraduate module on occlusion and a member of the multidisciplinary team for the TMD clinic. He has previous membership in the British Society for Restorative Dentistry, the Malaysian Association of Aesthetic Dentistry and he is currently a lifetime member of the Malaysian Association for Prosthodontics. Currently, he is also the examiner for the Restorative Specialty Membership Examinations, Royal College of Surgeons, England. He has authored and co-authored handful of both local and international journal articles. His main interest is in prosthodontics, dental material, TMD and regenerative dentistry.",institutionString:null,institution:{name:"University of Malaya",institutionURL:null,country:{name:"Malaysia"}}},editorThree:null}]},overviewPageOFChapters:{paginationCount:27,paginationItems:[{id:"83092",title:"Novel Composites for Bone Tissue Engineering",doi:"10.5772/intechopen.106255",signatures:"Pugalanthipandian Sankaralingam, Poornimadevi Sakthivel and Vijayakumar Chinnaswamy Thangavel",slug:"novel-composites-for-bone-tissue-engineering",totalDownloads:0,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Biomimetics - Bridging the Gap",coverURL:"https://cdn.intechopen.com/books/images_new/11453.jpg",subseries:{id:"8",title:"Bioinspired Technology and Biomechanics"}}},{id:"82800",title:"Repurposing Drugs as Potential Therapeutics for the SARS-Cov-2 Viral Infection: Automatizing a Blind Molecular Docking High-throughput Pipeline",doi:"10.5772/intechopen.105792",signatures:"Aldo Herrera-Rodulfo, Mariana Andrade-Medina and Mauricio Carrillo-Tripp",slug:"repurposing-drugs-as-potential-therapeutics-for-the-sars-cov-2-viral-infection-automatizing-a-blind-",totalDownloads:7,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Molecular Docking - Recent Advances",coverURL:"https://cdn.intechopen.com/books/images_new/11451.jpg",subseries:{id:"7",title:"Bioinformatics and Medical Informatics"}}},{id:"82582",title:"Protecting Bioelectric Signals from Electromagnetic Interference in a Wireless World",doi:"10.5772/intechopen.105951",signatures:"David Marcarian",slug:"protecting-bioelectric-signals-from-electromagnetic-interference-in-a-wireless-world",totalDownloads:4,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Biosignal Processing",coverURL:"https://cdn.intechopen.com/books/images_new/11153.jpg",subseries:{id:"7",title:"Bioinformatics and Medical Informatics"}}},{id:"82586",title:"Fundamentals of Molecular Docking and Comparative Analysis of Protein–Small-Molecule Docking Approaches",doi:"10.5772/intechopen.105815",signatures:"Maden Sefika Feyza, Sezer Selin and Acuner Saliha Ece",slug:"fundamentals-of-molecular-docking-and-comparative-analysis-of-protein-small-molecule-docking-approac",totalDownloads:27,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Molecular Docking - Recent Advances",coverURL:"https://cdn.intechopen.com/books/images_new/11451.jpg",subseries:{id:"7",title:"Bioinformatics and Medical Informatics"}}}]},overviewPagePublishedBooks:{paginationCount:12,paginationItems:[{type:"book",id:"6692",title:"Medical and Biological Image Analysis",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/6692.jpg",slug:"medical-and-biological-image-analysis",publishedDate:"July 4th 2018",editedByType:"Edited by",bookSignature:"Robert Koprowski",hash:"e75f234a0fc1988d9816a94e4c724deb",volumeInSeries:1,fullTitle:"Medical and Biological Image Analysis",editors:[{id:"50150",title:"Prof.",name:"Robert",middleName:null,surname:"Koprowski",slug:"robert-koprowski",fullName:"Robert Koprowski",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002aYTYNQA4/Profile_Picture_1630478535317",biography:"Robert Koprowski, MD (1997), PhD (2003), Habilitation (2015), is an employee of the University of Silesia, Poland, Institute of Computer Science, Department of Biomedical Computer Systems. For 20 years, he has studied the analysis and processing of biomedical images, emphasizing the full automation of measurement for a large inter-individual variability of patients. Dr. Koprowski has authored more than a hundred research papers with dozens in impact factor (IF) journals and has authored or co-authored six books. Additionally, he is the author of several national and international patents in the field of biomedical devices and imaging. Since 2011, he has been a reviewer of grants and projects (including EU projects) in biomedical engineering.",institutionString:null,institution:{name:"University of Silesia",institutionURL:null,country:{name:"Poland"}}}]},{type:"book",id:"7218",title:"OCT",subtitle:"Applications in Ophthalmology",coverURL:"https://cdn.intechopen.com/books/images_new/7218.jpg",slug:"oct-applications-in-ophthalmology",publishedDate:"September 19th 2018",editedByType:"Edited by",bookSignature:"Michele Lanza",hash:"e3a3430cdfd6999caccac933e4613885",volumeInSeries:2,fullTitle:"OCT - Applications in Ophthalmology",editors:[{id:"240088",title:"Prof.",name:"Michele",middleName:null,surname:"Lanza",slug:"michele-lanza",fullName:"Michele Lanza",profilePictureURL:"https://mts.intechopen.com/storage/users/240088/images/system/240088.png",biography:"Michele Lanza is Associate Professor of Ophthalmology at Università della Campania, Luigi Vanvitelli, Napoli, Italy. His fields of interest are anterior segment disease, keratoconus, glaucoma, corneal dystrophies, and cataracts. His research topics include\nintraocular lens power calculation, eye modification induced by refractive surgery, glaucoma progression, and validation of new diagnostic devices in ophthalmology. \nHe has published more than 100 papers in international and Italian scientific journals, more than 60 in journals with impact factors, and chapters in international and Italian books. He has also edited two international books and authored more than 150 communications or posters for the most important international and Italian ophthalmology conferences.",institutionString:'University of Campania "Luigi Vanvitelli"',institution:{name:'University of Campania "Luigi Vanvitelli"',institutionURL:null,country:{name:"Italy"}}}]},{type:"book",id:"7560",title:"Non-Invasive Diagnostic Methods",subtitle:"Image Processing",coverURL:"https://cdn.intechopen.com/books/images_new/7560.jpg",slug:"non-invasive-diagnostic-methods-image-processing",publishedDate:"December 19th 2018",editedByType:"Edited by",bookSignature:"Mariusz Marzec and Robert Koprowski",hash:"d92fd8cf5a90a47f2b8a310837a5600e",volumeInSeries:3,fullTitle:"Non-Invasive Diagnostic Methods - Image Processing",editors:[{id:"253468",title:"Dr.",name:"Mariusz",middleName:null,surname:"Marzec",slug:"mariusz-marzec",fullName:"Mariusz Marzec",profilePictureURL:"https://mts.intechopen.com/storage/users/253468/images/system/253468.png",biography:"An assistant professor at Department of Biomedical Computer Systems, at Institute of Computer Science, Silesian University in Katowice. Scientific interests: computer analysis and processing of images, biomedical images, databases and programming languages. He is an author and co-author of scientific publications covering analysis and processing of biomedical images and development of database systems.",institutionString:"University of Silesia",institution:{name:"University of Silesia",institutionURL:null,country:{name:"Poland"}}}]},{type:"book",id:"6843",title:"Biomechanics",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/6843.jpg",slug:"biomechanics",publishedDate:"January 30th 2019",editedByType:"Edited by",bookSignature:"Hadi Mohammadi",hash:"85132976010be1d7f3dbd88662b785e5",volumeInSeries:4,fullTitle:"Biomechanics",editors:[{id:"212432",title:"Prof.",name:"Hadi",middleName:null,surname:"Mohammadi",slug:"hadi-mohammadi",fullName:"Hadi Mohammadi",profilePictureURL:"https://mts.intechopen.com/storage/users/212432/images/system/212432.jpeg",biography:"Dr. Hadi Mohammadi is a biomedical engineer with hands-on experience in the design and development of many engineering structures and medical devices through various projects that he has been involved in over the past twenty years. Dr. Mohammadi received his BSc. and MSc. degrees in Mechanical Engineering from Sharif University of Technology, Tehran, Iran, and his PhD. degree in Biomedical Engineering (biomaterials) from the University of Western Ontario. He was a postdoctoral trainee for almost four years at University of Calgary and Harvard Medical School. He is an industry innovator having created the technology to produce lifelike synthetic platforms that can be used for the simulation of almost all cardiovascular reconstructive surgeries. He’s been heavily involved in the design and development of cardiovascular devices and technology for the past 10 years. He is currently an Assistant Professor with the University of British Colombia, Canada.",institutionString:"University of British Columbia",institution:{name:"University of British Columbia",institutionURL:null,country:{name:"Canada"}}}]}]},openForSubmissionBooks:{paginationCount:0,paginationItems:[]},onlineFirstChapters:{paginationCount:20,paginationItems:[{id:"82526",title:"Deep Multiagent Reinforcement Learning Methods Addressing the Scalability Challenge",doi:"10.5772/intechopen.105627",signatures:"Theocharis Kravaris and George A. Vouros",slug:"deep-multiagent-reinforcement-learning-methods-addressing-the-scalability-challenge",totalDownloads:19,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Multi-Agent Technologies and Machine Learning",coverURL:"https://cdn.intechopen.com/books/images_new/11445.jpg",subseries:{id:"27",title:"Multi-Agent Systems"}}},{id:"82196",title:"Multi-Features Assisted Age Invariant Face Recognition and Retrieval Using CNN with Scale Invariant Heat Kernel Signature",doi:"10.5772/intechopen.104944",signatures:"Kamarajugadda Kishore Kumar and Movva Pavani",slug:"multi-features-assisted-age-invariant-face-recognition-and-retrieval-using-cnn-with-scale-invariant-",totalDownloads:14,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Pattern Recognition - New Insights",coverURL:"https://cdn.intechopen.com/books/images_new/11442.jpg",subseries:{id:"26",title:"Machine Learning and Data Mining"}}},{id:"82063",title:"Evaluating Similarities and Differences between Machine Learning and Traditional Statistical Modeling in Healthcare Analytics",doi:"10.5772/intechopen.105116",signatures:"Michele Bennett, Ewa J. Kleczyk, Karin Hayes and Rajesh Mehta",slug:"evaluating-similarities-and-differences-between-machine-learning-and-traditional-statistical-modelin",totalDownloads:7,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Machine Learning and Data Mining - Annual Volume 2022",coverURL:"https://cdn.intechopen.com/books/images_new/11422.jpg",subseries:{id:"26",title:"Machine Learning and Data Mining"}}},{id:"81791",title:"Self-Supervised Contrastive Representation Learning in Computer Vision",doi:"10.5772/intechopen.104785",signatures:"Yalin Bastanlar and Semih Orhan",slug:"self-supervised-contrastive-representation-learning-in-computer-vision",totalDownloads:59,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Pattern Recognition - New Insights",coverURL:"https://cdn.intechopen.com/books/images_new/11442.jpg",subseries:{id:"26",title:"Machine Learning and Data Mining"}}},{id:"79345",title:"Application of Jump Diffusion Models in Insurance Claim Estimation",doi:"10.5772/intechopen.99853",signatures:"Leonard Mushunje, Chiedza Elvina Mashiri, Edina Chandiwana and Maxwell Mashasha",slug:"application-of-jump-diffusion-models-in-insurance-claim-estimation",totalDownloads:15,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Data Clustering",coverURL:"https://cdn.intechopen.com/books/images_new/10820.jpg",subseries:{id:"26",title:"Machine Learning and Data Mining"}}},{id:"81557",title:"Object Tracking Using Adapted Optical Flow",doi:"10.5772/intechopen.102863",signatures:"Ronaldo Ferreira, Joaquim José de Castro Ferreira and António José Ribeiro Neves",slug:"object-tracking-using-adapted-optical-flow",totalDownloads:23,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Information Extraction and Object Tracking in Digital Video",coverURL:"https://cdn.intechopen.com/books/images_new/10652.jpg",subseries:{id:"24",title:"Computer Vision"}}},{id:"81558",title:"Thresholding Image Techniques for Plant Segmentation",doi:"10.5772/intechopen.104587",signatures:"Miguel Ángel Castillo-Martínez, Francisco Javier Gallegos-Funes, Blanca E. Carvajal-Gámez, Guillermo Urriolagoitia-Sosa and Alberto J. Rosales-Silva",slug:"thresholding-image-techniques-for-plant-segmentation",totalDownloads:26,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Information Extraction and Object Tracking in Digital Video",coverURL:"https://cdn.intechopen.com/books/images_new/10652.jpg",subseries:{id:"24",title:"Computer Vision"}}},{id:"81471",title:"Semantic Map: Bringing Together Groups and Discourses",doi:"10.5772/intechopen.103818",signatures:"Theodore Chadjipadelis and Georgia Panagiotidou",slug:"semantic-map-bringing-together-groups-and-discourses",totalDownloads:25,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Data Clustering",coverURL:"https://cdn.intechopen.com/books/images_new/10820.jpg",subseries:{id:"26",title:"Machine Learning and Data Mining"}}},{id:"79491",title:"Fuzzy Perceptron Learning for Non-Linearly Separable Patterns",doi:"10.5772/intechopen.101312",signatures:"Raja Kishor Duggirala",slug:"fuzzy-perceptron-learning-for-non-linearly-separable-patterns",totalDownloads:20,totalCrossrefCites:0,totalDimensionsCites:0,authors:[{name:"Raja Kishor",surname:"Duggirala"}],book:{title:"Data Clustering",coverURL:"https://cdn.intechopen.com/books/images_new/10820.jpg",subseries:{id:"26",title:"Machine Learning and Data Mining"}}},{id:"81234",title:"Cognitive Visual Tracking of Hand Gestures in Real-Time RGB Videos",doi:"10.5772/intechopen.103170",signatures:"Richa Golash and Yogendra Kumar Jain",slug:"cognitive-visual-tracking-of-hand-gestures-in-real-time-rgb-videos",totalDownloads:50,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Information Extraction and Object Tracking in Digital Video",coverURL:"https://cdn.intechopen.com/books/images_new/10652.jpg",subseries:{id:"24",title:"Computer Vision"}}}]},subseriesFiltersForOFChapters:[{caption:"Applied Intelligence",value:22,count:1,group:"subseries"},{caption:"Multi-Agent Systems",value:27,count:1,group:"subseries"},{caption:"Computer Vision",value:24,count:8,group:"subseries"},{caption:"Machine Learning and Data Mining",value:26,count:10,group:"subseries"}],publishedBooks:{paginationCount:33,paginationItems:[{type:"book",id:"10840",title:"Benzimidazole",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/10840.jpg",slug:"benzimidazole",publishedDate:"July 13th 2022",editedByType:"Edited by",bookSignature:"Pravin Kendrekar and Vinayak Adimule",hash:"e28c770013e7a8dd0fc37aea6aa9def8",volumeInSeries:34,fullTitle:"Benzimidazole",editors:[{id:"310674",title:"Dr.",name:"Pravin",middleName:null,surname:"Kendrekar",slug:"pravin-kendrekar",fullName:"Pravin Kendrekar",profilePictureURL:"https://mts.intechopen.com/storage/users/310674/images/system/310674.jpg",institutionString:"Visiting Scientist at Lipid Nanostructures Laboratory, Centre for Smart Materials, School of Natural Sciences, University of Central Lancashire",institution:null}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"10798",title:"Starch",subtitle:"Evolution and Recent Advances",coverURL:"https://cdn.intechopen.com/books/images_new/10798.jpg",slug:"starch-evolution-and-recent-advances",publishedDate:"June 28th 2022",editedByType:"Edited by",bookSignature:"Martins Ochubiojo Emeje",hash:"f197f6062c1574a9a90e50a369271bcf",volumeInSeries:33,fullTitle:"Starch - Evolution and Recent Advances",editors:[{id:"94311",title:"Prof.",name:"Martins",middleName:"Ochubiojo",surname:"Ochubiojo Emeje",slug:"martins-ochubiojo-emeje",fullName:"Martins Ochubiojo Emeje",profilePictureURL:"https://mts.intechopen.com/storage/users/94311/images/system/94311.jpeg",institutionString:"National Institute for Pharmaceutical Research and Development",institution:{name:"National Institute for Pharmaceutical Research and Development",institutionURL:null,country:{name:"Nigeria"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"11332",title:"Essential Oils",subtitle:"Advances in Extractions and Biological Applications",coverURL:"https://cdn.intechopen.com/books/images_new/11332.jpg",slug:"essential-oils-advances-in-extractions-and-biological-applications",publishedDate:"June 23rd 2022",editedByType:"Edited by",bookSignature:"Mozaniel Santana de Oliveira and Eloisa Helena de Aguiar Andrade",hash:"742e6cae3a35686f975edc8d7f9afa94",volumeInSeries:32,fullTitle:"Essential Oils - Advances in Extractions and Biological Applications",editors:[{id:"195290",title:"Ph.D.",name:"Mozaniel",middleName:null,surname:"Santana De Oliveira",slug:"mozaniel-santana-de-oliveira",fullName:"Mozaniel Santana De Oliveira",profilePictureURL:"https://mts.intechopen.com/storage/users/195290/images/system/195290.png",institutionString:"Museu Paraense Emílio Goeldi",institution:{name:"Museu Paraense Emílio Goeldi",institutionURL:null,country:{name:"Brazil"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"10839",title:"Protein Detection",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/10839.jpg",slug:"protein-detection",publishedDate:"June 23rd 2022",editedByType:"Edited by",bookSignature:"Yusuf Tutar and Lütfi Tutar",hash:"2f1c0e4e0207fc45c936e7d22a5369c4",volumeInSeries:31,fullTitle:"Protein Detection",editors:[{id:"158492",title:"Prof.",name:"Yusuf",middleName:null,surname:"Tutar",slug:"yusuf-tutar",fullName:"Yusuf Tutar",profilePictureURL:"https://mts.intechopen.com/storage/users/158492/images/system/158492.jpeg",institutionString:"University of Health Sciences",institution:null}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"10797",title:"Cell Culture",subtitle:"Advanced Technology and Applications in Medical and Life Sciences",coverURL:"https://cdn.intechopen.com/books/images_new/10797.jpg",slug:"cell-culture-advanced-technology-and-applications-in-medical-and-life-sciences",publishedDate:"June 15th 2022",editedByType:"Edited by",bookSignature:"Xianquan Zhan",hash:"2c628f4757f9639a4450728d839a7842",volumeInSeries:30,fullTitle:"Cell Culture - Advanced Technology and Applications in Medical and Life Sciences",editors:[{id:"223233",title:"Prof.",name:"Xianquan",middleName:null,surname:"Zhan",slug:"xianquan-zhan",fullName:"Xianquan Zhan",profilePictureURL:"https://mts.intechopen.com/storage/users/223233/images/system/223233.png",institutionString:"Shandong First Medical University",institution:null}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"10841",title:"Hydrolases",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/10841.jpg",slug:"hydrolases",publishedDate:"June 15th 2022",editedByType:"Edited by",bookSignature:"Sajjad Haider, Adnan Haider and Angel Catalá",hash:"4e868cde273d65a7ff54b1817d640629",volumeInSeries:29,fullTitle:"Hydrolases",editors:[{id:"110708",title:"Dr.",name:"Sajjad",middleName:null,surname:"Haider",slug:"sajjad-haider",fullName:"Sajjad Haider",profilePictureURL:"https://mts.intechopen.com/storage/users/110708/images/system/110708.png",institutionString:"King Saud University",institution:{name:"King Saud University",institutionURL:null,country:{name:"Saudi Arabia"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"10803",title:"Reactive Oxygen Species",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/10803.jpg",slug:"reactive-oxygen-species",publishedDate:"April 28th 2022",editedByType:"Edited by",bookSignature:"Rizwan Ahmad",hash:"176adcf090fdd1f93cb8ce3146e79ca1",volumeInSeries:28,fullTitle:"Reactive Oxygen Species",editors:[{id:"40482",title:null,name:"Rizwan",middleName:null,surname:"Ahmad",slug:"rizwan-ahmad",fullName:"Rizwan Ahmad",profilePictureURL:"https://mts.intechopen.com/storage/users/40482/images/system/40482.jpeg",institutionString:"Imam Abdulrahman Bin Faisal University",institution:{name:"Imam Abdulrahman Bin Faisal University",institutionURL:null,country:{name:"Saudi Arabia"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"9008",title:"Vitamin K",subtitle:"Recent Topics on the Biology and Chemistry",coverURL:"https://cdn.intechopen.com/books/images_new/9008.jpg",slug:"vitamin-k-recent-topics-on-the-biology-and-chemistry",publishedDate:"March 23rd 2022",editedByType:"Edited by",bookSignature:"Hiroyuki Kagechika and Hitoshi Shirakawa",hash:"8b43add5389ba85743e0a9491e4b9943",volumeInSeries:27,fullTitle:"Vitamin K - Recent Topics on the Biology and Chemistry",editors:[{id:"180528",title:"Dr.",name:"Hiroyuki",middleName:null,surname:"Kagechika",slug:"hiroyuki-kagechika",fullName:"Hiroyuki Kagechika",profilePictureURL:"https://mts.intechopen.com/storage/users/180528/images/system/180528.jpg",institutionString:"Tokyo Medical and Dental University",institution:{name:"Tokyo Medical and Dental University",institutionURL:null,country:{name:"Japan"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"10799",title:"Phenolic Compounds",subtitle:"Chemistry, Synthesis, Diversity, Non-Conventional Industrial, Pharmaceutical and Therapeutic Applications",coverURL:"https://cdn.intechopen.com/books/images_new/10799.jpg",slug:"phenolic-compounds-chemistry-synthesis-diversity-non-conventional-industrial-pharmaceutical-and-therapeutic-applications",publishedDate:"February 23rd 2022",editedByType:"Edited by",bookSignature:"Farid A. Badria",hash:"339199f254d2987ef3167eef74fb8a38",volumeInSeries:26,fullTitle:"Phenolic Compounds - Chemistry, Synthesis, Diversity, Non-Conventional Industrial, Pharmaceutical and Therapeutic Applications",editors:[{id:"41865",title:"Prof.",name:"Farid A.",middleName:null,surname:"Badria",slug:"farid-a.-badria",fullName:"Farid A. Badria",profilePictureURL:"https://mts.intechopen.com/storage/users/41865/images/system/41865.jpg",institutionString:"Mansoura University",institution:{name:"Mansoura University",institutionURL:null,country:{name:"Egypt"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"9659",title:"Fibroblasts",subtitle:"Advances in Inflammation, Autoimmunity and Cancer",coverURL:"https://cdn.intechopen.com/books/images_new/9659.jpg",slug:"fibroblasts-advances-in-inflammation-autoimmunity-and-cancer",publishedDate:"December 22nd 2021",editedByType:"Edited by",bookSignature:"Mojca Frank Bertoncelj and Katja Lakota",hash:"926fa6446f6befbd363fc74971a56de2",volumeInSeries:25,fullTitle:"Fibroblasts - Advances in Inflammation, Autoimmunity and Cancer",editors:[{id:"328755",title:"Ph.D.",name:"Mojca",middleName:null,surname:"Frank Bertoncelj",slug:"mojca-frank-bertoncelj",fullName:"Mojca Frank Bertoncelj",profilePictureURL:"https://mts.intechopen.com/storage/users/328755/images/system/328755.jpg",institutionString:"BioMed X Institute",institution:{name:"University Hospital of Zurich",institutionURL:null,country:{name:"Switzerland"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"8977",title:"Protein Kinases",subtitle:"Promising Targets for Anticancer Drug Research",coverURL:"https://cdn.intechopen.com/books/images_new/8977.jpg",slug:"protein-kinases-promising-targets-for-anticancer-drug-research",publishedDate:"December 8th 2021",editedByType:"Edited by",bookSignature:"Rajesh Kumar Singh",hash:"6d200cc031706a565b554fdb1c478901",volumeInSeries:24,fullTitle:"Protein Kinases - Promising Targets for Anticancer Drug Research",editors:[{id:"329385",title:"Dr.",name:"Rajesh K.",middleName:"Kumar",surname:"Singh",slug:"rajesh-k.-singh",fullName:"Rajesh K. Singh",profilePictureURL:"https://mts.intechopen.com/storage/users/329385/images/system/329385.png",institutionString:"Punjab Technical University",institution:{name:"Punjab Technical University",institutionURL:null,country:{name:"India"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"8018",title:"Extracellular Matrix",subtitle:"Developments and Therapeutics",coverURL:"https://cdn.intechopen.com/books/images_new/8018.jpg",slug:"extracellular-matrix-developments-and-therapeutics",publishedDate:"October 27th 2021",editedByType:"Edited by",bookSignature:"Rama Sashank Madhurapantula, Joseph Orgel P.R.O. and Zvi Loewy",hash:"c85e82851e80b40282ff9be99ddf2046",volumeInSeries:23,fullTitle:"Extracellular Matrix - Developments and Therapeutics",editors:[{id:"212416",title:"Dr.",name:"Rama Sashank",middleName:null,surname:"Madhurapantula",slug:"rama-sashank-madhurapantula",fullName:"Rama Sashank Madhurapantula",profilePictureURL:"https://mts.intechopen.com/storage/users/212416/images/system/212416.jpg",institutionString:"Illinois Institute of Technology",institution:{name:"Illinois Institute of Technology",institutionURL:null,country:{name:"United States of America"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null}]},subseriesFiltersForPublishedBooks:[{group:"subseries",caption:"Proteomics",value:18,count:4},{group:"subseries",caption:"Metabolism",value:17,count:6},{group:"subseries",caption:"Cell and Molecular Biology",value:14,count:9},{group:"subseries",caption:"Chemical Biology",value:15,count:14}],publicationYearFilters:[{group:"publicationYear",caption:"2022",value:2022,count:9},{group:"publicationYear",caption:"2021",value:2021,count:7},{group:"publicationYear",caption:"2020",value:2020,count:12},{group:"publicationYear",caption:"2019",value:2019,count:3},{group:"publicationYear",caption:"2018",value:2018,count:2}],authors:{paginationCount:303,paginationItems:[{id:"280338",title:"Dr.",name:"Yutaka",middleName:null,surname:"Tsutsumi",slug:"yutaka-tsutsumi",fullName:"Yutaka Tsutsumi",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/280338/images/7961_n.jpg",biography:null,institutionString:null,institution:{name:"Fujita Health University",country:{name:"Japan"}}},{id:"116250",title:"Dr.",name:"Nima",middleName:null,surname:"Rezaei",slug:"nima-rezaei",fullName:"Nima Rezaei",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/116250/images/system/116250.jpg",biography:"Professor Nima Rezaei obtained an MD from Tehran University of Medical Sciences, Iran. He also obtained an MSc in Molecular and Genetic Medicine, and a Ph.D. in Clinical Immunology and Human Genetics from the University of Sheffield, UK. He also completed a short-term fellowship in Pediatric Clinical Immunology and Bone Marrow Transplantation at Newcastle General Hospital, England. Dr. Rezaei is a Full Professor of Immunology and Vice Dean of International Affairs and Research, at the School of Medicine, Tehran University of Medical Sciences, and the co-founder and head of the Research Center for Immunodeficiencies. He is also the founding president of the Universal Scientific Education and Research Network (USERN). Dr. Rezaei has directed more than 100 research projects and has designed and participated in several international collaborative projects. He is an editor, editorial assistant, or editorial board member of more than forty international journals. He has edited more than 50 international books, presented more than 500 lectures/posters in congresses/meetings, and published more than 1,100 scientific papers in international journals.",institutionString:"Tehran University of Medical Sciences",institution:{name:"Tehran University of Medical Sciences",country:{name:"Iran"}}},{id:"180733",title:"Dr.",name:"Jean",middleName:null,surname:"Engohang-Ndong",slug:"jean-engohang-ndong",fullName:"Jean Engohang-Ndong",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/180733/images/system/180733.png",biography:"Dr. Jean Engohang-Ndong was born and raised in Gabon. After obtaining his Associate Degree of Science at the University of Science and Technology of Masuku, Gabon, he continued his education in France where he obtained his BS, MS, and Ph.D. in Medical Microbiology. He worked as a post-doctoral fellow at the Public Health Research Institute (PHRI), Newark, NJ for four years before accepting a three-year faculty position at Brigham Young University-Hawaii. Dr. Engohang-Ndong is a tenured faculty member with the academic rank of Full Professor at Kent State University, Ohio, where he teaches a wide range of biological science courses and pursues his research in medical and environmental microbiology. Recently, he expanded his research interest to epidemiology and biostatistics of chronic diseases in Gabon.",institutionString:"Kent State University",institution:{name:"Kent State University",country:{name:"United States of America"}}},{id:"188773",title:"Prof.",name:"Emmanuel",middleName:null,surname:"Drouet",slug:"emmanuel-drouet",fullName:"Emmanuel Drouet",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/188773/images/system/188773.png",biography:"Emmanuel Drouet, PharmD, is a Professor of Virology at the Faculty of Pharmacy, the University Grenoble-Alpes, France. As a head scientist at the Institute of Structural Biology in Grenoble, Dr. Drouet’s research investigates persisting viruses in humans (RNA and DNA viruses) and the balance with our host immune system. He focuses on these viruses’ effects on humans (both their impact on pathology and their symbiotic relationships in humans). He has an excellent track record in the herpesvirus field, and his group is engaged in clinical research in the field of Epstein-Barr virus diseases. He is the editor of the online Encyclopedia of Environment and he coordinates the Universal Health Coverage education program for the BioHealth Computing Schools of the European Institute of Science.",institutionString:null,institution:{name:"Grenoble Alpes University",country:{name:"France"}}},{id:"131400",title:"Prof.",name:"Alfonso J.",middleName:null,surname:"Rodriguez-Morales",slug:"alfonso-j.-rodriguez-morales",fullName:"Alfonso J. Rodriguez-Morales",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/131400/images/system/131400.png",biography:"Dr. Rodriguez-Morales is an expert in tropical and emerging diseases, particularly zoonotic and vector-borne diseases (especially arboviral diseases). He is the president of the Travel Medicine Committee of the Pan-American Infectious Diseases Association (API), as well as the president of the Colombian Association of Infectious Diseases (ACIN). He is a member of the Committee on Tropical Medicine, Zoonoses, and Travel Medicine of ACIN. He is a vice-president of the Latin American Society for Travel Medicine (SLAMVI) and a Member of the Council of the International Society for Infectious Diseases (ISID). Since 2014, he has been recognized as a Senior Researcher, at the Ministry of Science of Colombia. He is a professor at the Faculty of Medicine of the Fundacion Universitaria Autonoma de las Americas, in Pereira, Risaralda, Colombia. He is an External Professor, Master in Research on Tropical Medicine and International Health, Universitat de Barcelona, Spain. He is also a professor at the Master in Clinical Epidemiology and Biostatistics, Universidad Científica del Sur, Lima, Peru. In 2021 he has been awarded the “Raul Isturiz Award” Medal of the API. Also, in 2021, he was awarded with the “Jose Felix Patiño” Asclepius Staff Medal of the Colombian Medical College, due to his scientific contributions to COVID-19 during the pandemic. He is currently the Editor in Chief of the journal Travel Medicine and Infectious Diseases. His Scopus H index is 47 (Google Scholar H index, 68).",institutionString:"Institución Universitaria Visión de las Américas, Colombia",institution:null},{id:"332819",title:"Dr.",name:"Chukwudi Michael",middleName:"Michael",surname:"Egbuche",slug:"chukwudi-michael-egbuche",fullName:"Chukwudi Michael Egbuche",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/332819/images/14624_n.jpg",biography:"I an Dr. Chukwudi Michael Egbuche. I am a Senior Lecturer in the Department of Parasitology and Entomology, Nnamdi Azikiwe University, Awka.",institutionString:null,institution:{name:"Nnamdi Azikiwe University",country:{name:"Nigeria"}}},{id:"284232",title:"Mr.",name:"Nikunj",middleName:"U",surname:"Tandel",slug:"nikunj-tandel",fullName:"Nikunj Tandel",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/284232/images/8275_n.jpg",biography:'Mr. Nikunj Tandel has completed his Master\'s degree in Biotechnology from VIT University, India in the year of 2012. He is having 8 years of research experience especially in the field of malaria epidemiology, immunology, and nanoparticle-based drug delivery system against the infectious diseases, autoimmune disorders and cancer. He has worked for the NIH funded-International Center of Excellence in Malaria Research project "Center for the study of complex malaria in India (CSCMi)" in collaboration with New York University. The preliminary objectives of the study are to understand and develop the evidence-based tools and interventions for the control and prevention of malaria in different sites of the INDIA. Alongside, with the help of next-generation genomics study, the team has studied the antimalarial drug resistance in India. Further, he has extended his research in the development of Humanized mice for the study of liver-stage malaria and identification of molecular marker(s) for the Artemisinin resistance. At present, his research focuses on understanding the role of B cells in the activation of CD8+ T cells in malaria. Received the CSIR-SRF (Senior Research Fellow) award-2018, FIMSA (Federation of Immunological Societies of Asia-Oceania) Travel Bursary award to attend the IUIS-IIS-FIMSA Immunology course-2019',institutionString:"Nirma University",institution:{name:"Nirma University",country:{name:"India"}}},{id:"334383",title:"Ph.D.",name:"Simone",middleName:"Ulrich",surname:"Ulrich Picoli",slug:"simone-ulrich-picoli",fullName:"Simone Ulrich Picoli",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/334383/images/15919_n.jpg",biography:"Graduated in Pharmacy from Universidade Luterana do Brasil (1999), Master in Agricultural and Environmental Microbiology from Federal University of Rio Grande do Sul (2002), Specialization in Clinical Microbiology from Universidade de São Paulo, USP (2007) and PhD in Sciences in Gastroenterology and Hepatology (2012). She is currently an Adjunct Professor at Feevale University in Medicine and Biomedicine courses and a permanent professor of the Academic Master\\'s Degree in Virology. She has experience in the field of Microbiology, with an emphasis on Bacteriology, working mainly on the following topics: bacteriophages, bacterial resistance, clinical microbiology and food microbiology.",institutionString:null,institution:{name:"Universidade Feevale",country:{name:"Brazil"}}},{id:"229220",title:"Dr.",name:"Amjad",middleName:"Islam",surname:"Aqib",slug:"amjad-aqib",fullName:"Amjad Aqib",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/229220/images/system/229220.png",biography:"Dr. Amjad Islam Aqib obtained a DVM and MSc (Hons) from University of Agriculture Faisalabad (UAF), Pakistan, and a PhD from the University of Veterinary and Animal Sciences Lahore, Pakistan. Dr. Aqib joined the Department of Clinical Medicine and Surgery at UAF for one year as an assistant professor where he developed a research laboratory designated for pathogenic bacteria. Since 2018, he has been Assistant Professor/Officer in-charge, Department of Medicine, Manager Research Operations and Development-ORIC, and President One Health Club at Cholistan University of Veterinary and Animal Sciences, Bahawalpur, Pakistan. He has nearly 100 publications to his credit. His research interests include epidemiological patterns and molecular analysis of antimicrobial resistance and modulation and vaccine development against animal pathogens of public health concern.",institutionString:"Cholistan University of Veterinary and Animal Sciences",institution:{name:"University of Agriculture Faisalabad",country:{name:"Pakistan"}}},{id:"333753",title:"Dr.",name:"Rais",middleName:null,surname:"Ahmed",slug:"rais-ahmed",fullName:"Rais Ahmed",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/333753/images/20168_n.jpg",biography:null,institutionString:null,institution:{name:"University of Agriculture Faisalabad",country:{name:"Pakistan"}}},{id:"62900",title:"Prof.",name:"Fethi",middleName:null,surname:"Derbel",slug:"fethi-derbel",fullName:"Fethi Derbel",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/62900/images/system/62900.jpeg",biography:"Professor Fethi Derbel was born in 1960 in Tunisia. He received his medical degree from the Sousse Faculty of Medicine at Sousse, University of Sousse, Tunisia. He completed his surgical residency in General Surgery at the University Hospital Farhat Hached of Sousse and was a member of the Unit of Liver Transplantation in the University of Rennes, France. He then worked in the Department of Surgery at the Sahloul University Hospital in Sousse. Professor Derbel is presently working at the Clinique les Oliviers, Sousse, Tunisia. His hospital activities are mostly concerned with laparoscopic, colorectal, pancreatic, hepatobiliary, and gastric surgery. He is also very interested in hernia surgery and performs ventral hernia repairs and inguinal hernia repairs. He has been a member of the GREPA and Tunisian Hernia Society (THS). During his residency, he managed patients suffering from diabetic foot, and he was very interested in this pathology. For this reason, he decided to coordinate a book project dealing with the diabetic foot. Professor Derbel has published many articles in journals and collaborates intensively with IntechOpen Access Publisher as an editor.",institutionString:"Clinique les Oliviers",institution:null},{id:"300144",title:"Dr.",name:"Meriem",middleName:null,surname:"Braiki",slug:"meriem-braiki",fullName:"Meriem Braiki",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/300144/images/system/300144.jpg",biography:"Dr. Meriem Braiki is a specialist in pediatric surgeon from Tunisia. She was born in 1985. She received her medical degree from the University of Medicine at Sousse, Tunisia. She achieved her surgical residency training periods in Pediatric Surgery departments at University Hospitals in Monastir, Tunis and France.\r\nShe is currently working at the Pediatric surgery department, Sidi Bouzid Hospital, Tunisia. Her hospital activities are mostly concerned with laparoscopic, parietal, urological and digestive surgery. She has published several articles in diffrent journals.",institutionString:"Sidi Bouzid Regional Hospital",institution:null},{id:"229481",title:"Dr.",name:"Erika M.",middleName:"Martins",surname:"de Carvalho",slug:"erika-m.-de-carvalho",fullName:"Erika M. de Carvalho",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/229481/images/6397_n.jpg",biography:null,institutionString:null,institution:{name:"Oswaldo Cruz Foundation",country:{name:"Brazil"}}},{id:"186537",title:"Prof.",name:"Tonay",middleName:null,surname:"Inceboz",slug:"tonay-inceboz",fullName:"Tonay Inceboz",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/186537/images/system/186537.jfif",biography:"I was graduated from Ege University of Medical Faculty (Turkey) in 1988 and completed his Med. PhD degree in Medical Parasitology at the same university. I became an Associate Professor in 2008 and Professor in 2014. I am currently working as a Professor at the Department of Medical Parasitology at Dokuz Eylul University, Izmir, Turkey.\n\nI have given many lectures, presentations in different academic meetings. I have more than 60 articles in peer-reviewed journals, 18 book chapters, 1 book editorship.\n\nMy research interests are Echinococcus granulosus, Echinococcus multilocularis (diagnosis, life cycle, in vitro and in vivo cultivation), and Trichomonas vaginalis (diagnosis, PCR, and in vitro cultivation).",institutionString:"Dokuz Eylül University",institution:{name:"Dokuz Eylül University",country:{name:"Turkey"}}},{id:"71812",title:"Prof.",name:"Hanem Fathy",middleName:"Fathy",surname:"Khater",slug:"hanem-fathy-khater",fullName:"Hanem Fathy Khater",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/71812/images/1167_n.jpg",biography:"Prof. Khater is a Professor of Parasitology at Benha University, Egypt. She studied for her doctoral degree, at the Department of Entomology, College of Agriculture, Food and Natural Resources, University of Missouri, Columbia, USA. She has completed her Ph.D. degrees in Parasitology in Egypt, from where she got the award for “the best scientific Ph.D. dissertation”. She worked at the School of Biological Sciences, Bristol, England, the UK in controlling insects of medical and veterinary importance as a grant from Newton Mosharafa, the British Council. Her research is focused on searching of pesticides against mosquitoes, house flies, lice, green bottle fly, camel nasal botfly, soft and hard ticks, mites, and the diamondback moth as well as control of several parasites using safe and natural materials to avoid drug resistances and environmental contamination.",institutionString:null,institution:{name:"Banha University",country:{name:"Egypt"}}},{id:"99780",title:"Prof.",name:"Omolade",middleName:"Olayinka",surname:"Okwa",slug:"omolade-okwa",fullName:"Omolade Okwa",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/99780/images/system/99780.jpg",biography:"Omolade Olayinka Okwa is presently a Professor of Parasitology at Lagos State University, Nigeria. She has a PhD in Parasitology (1997), an MSc in Cellular Parasitology (1992), and a BSc (Hons) Zoology (1990) all from the University of Ibadan, Nigeria. She teaches parasitology at the undergraduate and postgraduate levels. She was a recipient of a Commonwealth fellowship supported by British Council tenable at the Centre for Entomology and Parasitology (CAEP), Keele University, United Kingdom between 2004 and 2005. She was awarded an Honorary Visiting Research Fellow at the same university from 2005 to 2007. \nShe has been an external examiner to the Department of Veterinary Microbiology and Parasitology, University of Ibadan, MSc programme between 2010 and 2012. She is a member of the Nigerian Society of Experimental Biology (NISEB), Parasitology and Public Health Society of Nigeria (PPSN), Science Association of Nigeria (SAN), Zoological Society of Nigeria (ZSN), and is Vice Chairperson of the Organisation of Women in Science (OWSG), LASU chapter. She served as Head of Department of Zoology and Environmental Biology, Lagos State University from 2007 to 2010 and 2014 to 2016. She is a reviewer for several local and international journals such as Unilag Journal of Science, Libyan Journal of Medicine, Journal of Medicine and Medical Sciences, and Annual Research and Review in Science. \nShe has authored 45 scientific research publications in local and international journals, 8 scientific reviews, 4 books, and 3 book chapters, which includes the books “Malaria Parasites” and “Malaria” which are IntechOpen access publications.",institutionString:"Lagos State University",institution:{name:"Lagos State University",country:{name:"Nigeria"}}},{id:"273100",title:"Dr.",name:"Vijay",middleName:null,surname:"Gayam",slug:"vijay-gayam",fullName:"Vijay Gayam",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/273100/images/system/273100.jpeg",biography:"Dr. Vijay Bhaskar Reddy Gayam is currently practicing as an internist at Interfaith Medical Center in Brooklyn, New York, USA. He is also a Clinical Assistant Professor at the SUNY Downstate University Hospital and Adjunct Professor of Medicine at the American University of Antigua. He is a holder of an M.B.B.S. degree bestowed to him by Osmania Medical College and received his M.D. at Interfaith Medical Center. His career goals thus far have heavily focused on direct patient care, medical education, and clinical research. He currently serves in two leadership capacities; Assistant Program Director of Medicine at Interfaith Medical Center and as a Councilor for the American\r\nFederation for Medical Research. As a true academician and researcher, he has more than 50 papers indexed in international peer-reviewed journals. He has also presented numerous papers in multiple national and international scientific conferences. His areas of research interest include general internal medicine, gastroenterology and hepatology. He serves as an editor, editorial board member and reviewer for multiple international journals. His research on Hepatitis C has been very successful and has led to multiple research awards, including the 'Equity in Prevention and Treatment Award” from the New York Department of Health Viral Hepatitis Symposium (2018) and the 'Presidential Poster Award” awarded to him by the American College of Gastroenterology (2018). He was also awarded 'Outstanding Clinician in General Medicine” by Venus International Foundation for his extensive research expertise and services, perform over and above the standard expected in the advancement of healthcare, patient safety and quality of care.",institutionString:"Interfaith Medical Center",institution:{name:"Interfaith Medical Center",country:{name:"United States of America"}}},{id:"93517",title:"Dr.",name:"Clement",middleName:"Adebajo",surname:"Meseko",slug:"clement-meseko",fullName:"Clement Meseko",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/93517/images/system/93517.jpg",biography:"Dr. Clement Meseko obtained DVM and PhD degree in Veterinary Medicine and Virology respectively. He has worked for over 20 years in both private and public sectors including the academia, contributing to knowledge and control of infectious disease. Through the application of epidemiological skill, classical and molecular virological skills, he investigates viruses of economic and public health importance for the mitigation of the negative impact on people, animal and the environment in the context of Onehealth. \r\nDr. Meseko’s field experience on animal and zoonotic diseases and pathogen dynamics at the human-animal interface over the years shaped his carrier in research and scientific inquiries. He has been part of the investigation of Highly Pathogenic Avian Influenza incursions in sub Saharan Africa and monitors swine Influenza (Pandemic influenza Virus) agro-ecology and potential for interspecies transmission. He has authored and reviewed a number of journal articles and book chapters.",institutionString:"National Veterinary Research Institute",institution:{name:"National Veterinary Research Institute",country:{name:"Nigeria"}}},{id:"158026",title:"Prof.",name:"Shailendra K.",middleName:null,surname:"Saxena",slug:"shailendra-k.-saxena",fullName:"Shailendra K. Saxena",position:null,profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002bRET3QAO/Profile_Picture_2022-05-10T10:10:26.jpeg",biography:"Professor Dr. Shailendra K. Saxena is a vice dean and professor at King George's Medical University, Lucknow, India. His research interests involve understanding the molecular mechanisms of host defense during human viral infections and developing new predictive, preventive, and therapeutic strategies for them using Japanese encephalitis virus (JEV), HIV, and emerging viruses as a model via stem cell and cell culture technologies. His research work has been published in various high-impact factor journals (Science, PNAS, Nature Medicine) with a high number of citations. He has received many awards and honors in India and abroad including various Young Scientist Awards, BBSRC India Partnering Award, and Dr. JC Bose National Award of Department of Biotechnology, Min. of Science and Technology, Govt. of India. Dr. Saxena is a fellow of various international societies/academies including the Royal College of Pathologists, United Kingdom; Royal Society of Medicine, London; Royal Society of Biology, United Kingdom; Royal Society of Chemistry, London; and Academy of Translational Medicine Professionals, Austria. He was named a Global Leader in Science by The Scientist. He is also an international opinion leader/expert in vaccination for Japanese encephalitis by IPIC (UK).",institutionString:"King George's Medical University",institution:{name:"King George's Medical University",country:{name:"India"}}},{id:"94928",title:"Dr.",name:"Takuo",middleName:null,surname:"Mizukami",slug:"takuo-mizukami",fullName:"Takuo Mizukami",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/94928/images/6402_n.jpg",biography:null,institutionString:null,institution:{name:"National Institute of Infectious Diseases",country:{name:"Japan"}}},{id:"233433",title:"Dr.",name:"Yulia",middleName:null,surname:"Desheva",slug:"yulia-desheva",fullName:"Yulia Desheva",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/233433/images/system/233433.png",biography:"Dr. Yulia Desheva is a leading researcher at the Institute of Experimental Medicine, St. Petersburg, Russia. She is a professor in the Stomatology Faculty, St. Petersburg State University. She has expertise in the development and evaluation of a wide range of live mucosal vaccines against influenza and bacterial complications. Her research interests include immunity against influenza and COVID-19 and the development of immunization schemes for high-risk individuals.",institutionString:'Federal State Budgetary Scientific Institution "Institute of Experimental Medicine"',institution:null},{id:"238958",title:"Mr.",name:"Atamjit",middleName:null,surname:"Singh",slug:"atamjit-singh",fullName:"Atamjit Singh",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/238958/images/6575_n.jpg",biography:null,institutionString:null,institution:null},{id:"252058",title:"M.Sc.",name:"Juan",middleName:null,surname:"Sulca",slug:"juan-sulca",fullName:"Juan Sulca",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/252058/images/12834_n.jpg",biography:null,institutionString:null,institution:null},{id:"191392",title:"Dr.",name:"Marimuthu",middleName:null,surname:"Govindarajan",slug:"marimuthu-govindarajan",fullName:"Marimuthu Govindarajan",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/191392/images/5828_n.jpg",biography:"Dr. M. Govindarajan completed his BSc degree in Zoology at Government Arts College (Autonomous), Kumbakonam, and MSc, MPhil, and PhD degrees at Annamalai University, Annamalai Nagar, Tamil Nadu, India. He is serving as an assistant professor at the Department of Zoology, Annamalai University. His research interests include isolation, identification, and characterization of biologically active molecules from plants and microbes. He has identified more than 20 pure compounds with high mosquitocidal activity and also conducted high-quality research on photochemistry and nanosynthesis. He has published more than 150 studies in journals with impact factor and 2 books in Lambert Academic Publishing, Germany. He serves as an editorial board member in various national and international scientific journals.",institutionString:null,institution:null},{id:"274660",title:"Dr.",name:"Damodar",middleName:null,surname:"Paudel",slug:"damodar-paudel",fullName:"Damodar Paudel",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/274660/images/8176_n.jpg",biography:"I am DrDamodar Paudel,currently working as consultant Physician in Nepal police Hospital.",institutionString:null,institution:null},{id:"241562",title:"Dr.",name:"Melvin",middleName:null,surname:"Sanicas",slug:"melvin-sanicas",fullName:"Melvin Sanicas",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/241562/images/6699_n.jpg",biography:null,institutionString:null,institution:null},{id:"117248",title:"Dr.",name:"Andrew",middleName:null,surname:"Macnab",slug:"andrew-macnab",fullName:"Andrew Macnab",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"University of British Columbia",country:{name:"Canada"}}},{id:"322007",title:"Dr.",name:"Maria Elizbeth",middleName:null,surname:"Alvarez-Sánchez",slug:"maria-elizbeth-alvarez-sanchez",fullName:"Maria Elizbeth Alvarez-Sánchez",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Universidad Autónoma de la Ciudad de México",country:{name:"Mexico"}}},{id:"337443",title:"Dr.",name:"Juan",middleName:null,surname:"A. Gonzalez-Sanchez",slug:"juan-a.-gonzalez-sanchez",fullName:"Juan A. Gonzalez-Sanchez",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"University of Puerto Rico System",country:{name:"United States of America"}}},{id:"337446",title:"Dr.",name:"Maria",middleName:null,surname:"Zavala-Colon",slug:"maria-zavala-colon",fullName:"Maria Zavala-Colon",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"University of Puerto Rico, Medical Sciences Campus",country:{name:"United States of America"}}}]}},subseries:{item:{id:"5",type:"subseries",title:"Parasitic Infectious Diseases",keywords:"Blood Borne Parasites, Intestinal Parasites, Protozoa, Helminths, Arthropods, Water Born Parasites, Epidemiology, Molecular Biology, Systematics, Genomics, Proteomics, Ecology",scope:"Parasitic diseases have evolved alongside their human hosts. In many cases, these diseases have adapted so well that they have developed efficient resilience methods in the human host and can live in the host for years. Others, particularly some blood parasites, can cause very acute diseases and are responsible for millions of deaths yearly. Many parasitic diseases are classified as neglected tropical diseases because they have received minimal funding over recent years and, in many cases, are under-reported despite the critical role they play in morbidity and mortality among human and animal hosts. The current topic, Parasitic Infectious Diseases, in the Infectious Diseases Series aims to publish studies on the systematics, epidemiology, molecular biology, genomics, pathogenesis, genetics, and clinical significance of parasitic diseases from blood borne to intestinal parasites as well as zoonotic parasites. We hope to cover all aspects of parasitic diseases to provide current and relevant research data on these very important diseases. In the current atmosphere of the Coronavirus pandemic, communities around the world, particularly those in different underdeveloped areas, are faced with the growing challenges of the high burden of parasitic diseases. At the same time, they are faced with the Covid-19 pandemic leading to what some authors have called potential syndemics that might worsen the outcome of such infections. Therefore, it is important to conduct studies that examine parasitic infections in the context of the coronavirus pandemic for the benefit of all communities to help foster more informed decisions for the betterment of human and animal health.",coverUrl:"https://cdn.intechopen.com/series_topics/covers/5.jpg",hasOnlineFirst:!0,hasPublishedBooks:!0,annualVolume:11401,editor:{id:"67907",title:"Dr.",name:"Amidou",middleName:null,surname:"Samie",slug:"amidou-samie",fullName:"Amidou Samie",profilePictureURL:"https://mts.intechopen.com/storage/users/67907/images/system/67907.jpg",biography:"Dr. Amidou Samie is an Associate Professor of Microbiology at the University of Venda, in South Africa, where he graduated for his PhD in May 2008. He joined the Department of Microbiology the same year and has been giving lectures on topics covering parasitology, immunology, molecular biology and industrial microbiology. He is currently a rated researcher by the National Research Foundation of South Africa at category C2. He has published widely in the field of infectious diseases and has overseen several MSc’s and PhDs. His research activities mostly cover topics on infectious diseases from epidemiology to control. His particular interest lies in the study of intestinal protozoan parasites and opportunistic infections among HIV patients as well as the potential impact of childhood diarrhoea on growth and child development. He also conducts research on water-borne diseases and water quality and is involved in the evaluation of point-of-use water treatment technologies using silver and copper nanoparticles in collaboration with the University of Virginia, USA. He also studies the use of medicinal plants for the control of infectious diseases as well as antimicrobial drug resistance.",institutionString:null,institution:{name:"University of Venda",institutionURL:null,country:{name:"South Africa"}}},editorTwo:null,editorThree:null,series:{id:"6",title:"Infectious Diseases",doi:"10.5772/intechopen.71852",issn:"2631-6188"},editorialBoard:[{id:"188881",title:"Dr.",name:"Fernando José",middleName:null,surname:"Andrade-Narváez",slug:"fernando-jose-andrade-narvaez",fullName:"Fernando José Andrade-Narváez",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002bRIV7QAO/Profile_Picture_1628834308121",institutionString:null,institution:{name:"Autonomous University of Yucatán",institutionURL:null,country:{name:"Mexico"}}},{id:"269120",title:"Dr.",name:"Rajeev",middleName:"K.",surname:"Tyagi",slug:"rajeev-tyagi",fullName:"Rajeev Tyagi",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002bRaBqQAK/Profile_Picture_1644331884726",institutionString:"CSIR - Institute of Microbial Technology, India",institution:null},{id:"336849",title:"Prof.",name:"Ricardo",middleName:null,surname:"Izurieta",slug:"ricardo-izurieta",fullName:"Ricardo Izurieta",profilePictureURL:"https://mts.intechopen.com/storage/users/293169/images/system/293169.png",institutionString:null,institution:{name:"University of South Florida",institutionURL:null,country:{name:"United States of America"}}}]},onlineFirstChapters:{paginationCount:4,paginationItems:[{id:"83065",title:"Interventions and Practical Approaches to Reduce the Burden of Malaria on School-Aged Children",doi:"10.5772/intechopen.106469",signatures:"Andrew Macnab",slug:"interventions-and-practical-approaches-to-reduce-the-burden-of-malaria-on-school-aged-children",totalDownloads:4,totalCrossrefCites:0,totalDimensionsCites:0,authors:[{name:"Andrew",surname:"Macnab"}],book:{title:"Malaria - Recent Advances, and New Perspectives",coverURL:"https://cdn.intechopen.com/books/images_new/11576.jpg",subseries:{id:"5",title:"Parasitic Infectious Diseases"}}},{id:"82827",title:"Epidemiology and Control of Schistosomiasis",doi:"10.5772/intechopen.105170",signatures:"Célestin Kyambikwa Bisangamo",slug:"epidemiology-and-control-of-schistosomiasis",totalDownloads:6,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"New Horizons for Schistosomiasis Research",coverURL:"https://cdn.intechopen.com/books/images_new/10829.jpg",subseries:{id:"5",title:"Parasitic Infectious Diseases"}}},{id:"81972",title:"The Submicroscopic Plasmodium falciparum Malaria in Sub-Saharan Africa; Current Understanding of the Host Immune System and New Perspectives",doi:"10.5772/intechopen.105086",signatures:"Kwame Kumi Asare",slug:"the-submicroscopic-plasmodium-falciparum-malaria-in-sub-saharan-africa-current-understanding-of-the-",totalDownloads:5,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Malaria - Recent Advances, and New Perspectives",coverURL:"https://cdn.intechopen.com/books/images_new/11576.jpg",subseries:{id:"5",title:"Parasitic Infectious Diseases"}}},{id:"81813",title:"Schistosomiasis: Discovery of New Molecules for Disease Treatment and Vaccine Development",doi:"10.5772/intechopen.104738",signatures:"Andressa Barban do Patrocinio",slug:"schistosomiasis-discovery-of-new-molecules-for-disease-treatment-and-vaccine-development",totalDownloads:18,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"New Horizons for Schistosomiasis Research",coverURL:"https://cdn.intechopen.com/books/images_new/10829.jpg",subseries:{id:"5",title:"Parasitic Infectious Diseases"}}}]},publishedBooks:{paginationCount:9,paginationItems:[{type:"book",id:"9959",title:"Biomedical Signal and Image Processing",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/9959.jpg",slug:"biomedical-signal-and-image-processing",publishedDate:"April 14th 2021",editedByType:"Edited by",bookSignature:"Yongxia Zhou",hash:"22b87a09bd6df065d78c175235d367c8",volumeInSeries:10,fullTitle:"Biomedical Signal and Image Processing",editors:[{id:"259308",title:"Dr.",name:"Yongxia",middleName:null,surname:"Zhou",slug:"yongxia-zhou",fullName:"Yongxia Zhou",profilePictureURL:"https://mts.intechopen.com/storage/users/259308/images/system/259308.jpeg",institutionString:"University of Southern California",institution:{name:"University of Southern California",institutionURL:null,country:{name:"United States of America"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"9973",title:"Data Acquisition",subtitle:"Recent Advances and Applications in Biomedical Engineering",coverURL:"https://cdn.intechopen.com/books/images_new/9973.jpg",slug:"data-acquisition-recent-advances-and-applications-in-biomedical-engineering",publishedDate:"March 17th 2021",editedByType:"Edited by",bookSignature:"Bartłomiej Płaczek",hash:"75ea6cdd241216c9db28aa734ab34446",volumeInSeries:9,fullTitle:"Data Acquisition - Recent Advances and Applications in Biomedical Engineering",editors:[{id:"313277",title:"Dr.",name:"Bartłomiej",middleName:null,surname:"Płaczek",slug:"bartlomiej-placzek",fullName:"Bartłomiej Płaczek",profilePictureURL:"https://mts.intechopen.com/storage/users/313277/images/system/313277.jpg",institutionString:"University of Silesia",institution:{name:"University of Silesia",institutionURL:null,country:{name:"Poland"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"9905",title:"Biometric Systems",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/9905.jpg",slug:"biometric-systems",publishedDate:"February 10th 2021",editedByType:"Edited by",bookSignature:"Muhammad Sarfraz",hash:"c730560dd2e3837a03407b3a86b0ef2a",volumeInSeries:8,fullTitle:"Biometric Systems",editors:[{id:"215610",title:"Prof.",name:"Muhammad",middleName:null,surname:"Sarfraz",slug:"muhammad-sarfraz",fullName:"Muhammad Sarfraz",profilePictureURL:"https://mts.intechopen.com/storage/users/215610/images/system/215610.jpeg",institutionString:"Kuwait University",institution:{name:"Kuwait University",institutionURL:null,country:{name:"Kuwait"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"8622",title:"Peptide Synthesis",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/8622.jpg",slug:"peptide-synthesis",publishedDate:"December 18th 2019",editedByType:"Edited by",bookSignature:"Jaya T. Varkey",hash:"de9fa48c5248dbfb581825b8c74f5623",volumeInSeries:0,fullTitle:"Peptide Synthesis",editors:[{id:"246502",title:"Dr.",name:"Jaya T.",middleName:"T",surname:"Varkey",slug:"jaya-t.-varkey",fullName:"Jaya T. Varkey",profilePictureURL:"https://mts.intechopen.com/storage/users/246502/images/11160_n.jpg",institutionString:"St. Teresa’s College",institution:null}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"7497",title:"Computer Vision in Dentistry",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/7497.jpg",slug:"computer-vision-in-dentistry",publishedDate:"September 18th 2019",editedByType:"Edited by",bookSignature:"Monika Elzbieta Machoy",hash:"1e9812cebd46ef9e28257f3e96547f6a",volumeInSeries:7,fullTitle:"Computer Vision in Dentistry",editors:[{id:"248279",title:"Dr.",name:"Monika",middleName:"Elzbieta",surname:"Machoy",slug:"monika-machoy",fullName:"Monika Machoy",profilePictureURL:"https://mts.intechopen.com/storage/users/248279/images/system/248279.jpeg",institutionString:"Pomeranian Medical University",institution:{name:"Pomeranian Medical University",institutionURL:null,country:{name:"Poland"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"8633",title:"Novel Diagnostic Methods in Ophthalmology",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/8633.jpg",slug:"novel-diagnostic-methods-in-ophthalmology",publishedDate:"September 4th 2019",editedByType:"Edited by",bookSignature:"Anna Nowinska",hash:"da2c90e8db647ead30504defce3fb5d3",volumeInSeries:6,fullTitle:"Novel Diagnostic Methods in Ophthalmology",editors:[{id:"261466",title:"Dr.",name:"Anna",middleName:"Karolina",surname:"Nowińska",slug:"anna-nowinska",fullName:"Anna Nowińska",profilePictureURL:"https://mts.intechopen.com/storage/users/261466/images/system/261466.jpeg",institutionString:"Medical University of Silesia",institution:null}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"7560",title:"Non-Invasive Diagnostic Methods",subtitle:"Image Processing",coverURL:"https://cdn.intechopen.com/books/images_new/7560.jpg",slug:"non-invasive-diagnostic-methods-image-processing",publishedDate:"December 19th 2018",editedByType:"Edited by",bookSignature:"Mariusz Marzec and Robert Koprowski",hash:"d92fd8cf5a90a47f2b8a310837a5600e",volumeInSeries:3,fullTitle:"Non-Invasive Diagnostic Methods - Image Processing",editors:[{id:"253468",title:"Dr.",name:"Mariusz",middleName:null,surname:"Marzec",slug:"mariusz-marzec",fullName:"Mariusz Marzec",profilePictureURL:"https://mts.intechopen.com/storage/users/253468/images/system/253468.png",institutionString:"University of Silesia",institution:{name:"University of Silesia",institutionURL:null,country:{name:"Poland"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"7218",title:"OCT",subtitle:"Applications in Ophthalmology",coverURL:"https://cdn.intechopen.com/books/images_new/7218.jpg",slug:"oct-applications-in-ophthalmology",publishedDate:"September 19th 2018",editedByType:"Edited by",bookSignature:"Michele Lanza",hash:"e3a3430cdfd6999caccac933e4613885",volumeInSeries:2,fullTitle:"OCT - Applications in Ophthalmology",editors:[{id:"240088",title:"Prof.",name:"Michele",middleName:null,surname:"Lanza",slug:"michele-lanza",fullName:"Michele Lanza",profilePictureURL:"https://mts.intechopen.com/storage/users/240088/images/system/240088.png",institutionString:'University of Campania "Luigi Vanvitelli"',institution:{name:'University of Campania "Luigi Vanvitelli"',institutionURL:null,country:{name:"Italy"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"6692",title:"Medical and Biological Image Analysis",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/6692.jpg",slug:"medical-and-biological-image-analysis",publishedDate:"July 4th 2018",editedByType:"Edited by",bookSignature:"Robert Koprowski",hash:"e75f234a0fc1988d9816a94e4c724deb",volumeInSeries:1,fullTitle:"Medical and Biological Image Analysis",editors:[{id:"50150",title:"Prof.",name:"Robert",middleName:null,surname:"Koprowski",slug:"robert-koprowski",fullName:"Robert Koprowski",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002aYTYNQA4/Profile_Picture_1630478535317",institutionString:null,institution:{name:"University of Silesia",institutionURL:null,country:{name:"Poland"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null}]},testimonialsList:[{id:"18",text:"It was great publishing with IntechOpen, the process was straightforward and I had support all along.",author:{id:"71579",name:"Berend",surname:"Olivier",institutionString:"Utrecht University",profilePictureURL:"https://mts.intechopen.com/storage/users/71579/images/system/71579.png",slug:"berend-olivier",institution:{id:"253",name:"Utrecht University",country:{id:null,name:"Netherlands"}}}},{id:"27",text:"The opportunity to work with a prestigious publisher allows for the possibility to collaborate with more research groups interested in animal nutrition, leading to the development of new feeding strategies and food valuation while being more sustainable with the environment, allowing more readers to learn about the subject.",author:{id:"175967",name:"Manuel",surname:"Gonzalez Ronquillo",institutionString:null,profilePictureURL:"https://mts.intechopen.com/storage/users/175967/images/system/175967.png",slug:"manuel-gonzalez-ronquillo",institution:{id:"6221",name:"Universidad Autónoma del Estado de México",country:{id:null,name:"Mexico"}}}},{id:"8",text:"I work with IntechOpen for a number of reasons: their professionalism, their mission in support of Open Access publishing, and the quality of their peer-reviewed publications, but also because they believe in equality.",author:{id:"202192",name:"Catrin",surname:"Rutland",institutionString:null,profilePictureURL:"https://mts.intechopen.com/storage/users/202192/images/system/202192.png",slug:"catrin-rutland",institution:{id:"134",name:"University of Nottingham",country:{id:null,name:"United Kingdom"}}}}]},submityourwork:{pteSeriesList:[{id:"14",title:"Artificial Intelligence",numberOfPublishedBooks:9,numberOfPublishedChapters:90,numberOfOpenTopics:6,numberOfUpcomingTopics:0,issn:"2633-1403",doi:"10.5772/intechopen.79920",isOpenForSubmission:!0},{id:"7",title:"Biomedical Engineering",numberOfPublishedBooks:12,numberOfPublishedChapters:108,numberOfOpenTopics:3,numberOfUpcomingTopics:0,issn:"2631-5343",doi:"10.5772/intechopen.71985",isOpenForSubmission:!0}],lsSeriesList:[{id:"11",title:"Biochemistry",numberOfPublishedBooks:33,numberOfPublishedChapters:330,numberOfOpenTopics:4,numberOfUpcomingTopics:0,issn:"2632-0983",doi:"10.5772/intechopen.72877",isOpenForSubmission:!0},{id:"25",title:"Environmental Sciences",numberOfPublishedBooks:1,numberOfPublishedChapters:19,numberOfOpenTopics:4,numberOfUpcomingTopics:0,issn:"2754-6713",doi:"10.5772/intechopen.100362",isOpenForSubmission:!0},{id:"10",title:"Physiology",numberOfPublishedBooks:14,numberOfPublishedChapters:145,numberOfOpenTopics:4,numberOfUpcomingTopics:0,issn:"2631-8261",doi:"10.5772/intechopen.72796",isOpenForSubmission:!0}],hsSeriesList:[{id:"3",title:"Dentistry",numberOfPublishedBooks:9,numberOfPublishedChapters:141,numberOfOpenTopics:2,numberOfUpcomingTopics:0,issn:"2631-6218",doi:"10.5772/intechopen.71199",isOpenForSubmission:!0},{id:"6",title:"Infectious Diseases",numberOfPublishedBooks:13,numberOfPublishedChapters:123,numberOfOpenTopics:4,numberOfUpcomingTopics:0,issn:"2631-6188",doi:"10.5772/intechopen.71852",isOpenForSubmission:!0},{id:"13",title:"Veterinary Medicine and Science",numberOfPublishedBooks:11,numberOfPublishedChapters:112,numberOfOpenTopics:3,numberOfUpcomingTopics:0,issn:"2632-0517",doi:"10.5772/intechopen.73681",isOpenForSubmission:!0}],sshSeriesList:[{id:"22",title:"Business, Management and Economics",numberOfPublishedBooks:1,numberOfPublishedChapters:22,numberOfOpenTopics:3,numberOfUpcomingTopics:0,issn:"2753-894X",doi:"10.5772/intechopen.100359",isOpenForSubmission:!0},{id:"23",title:"Education and Human Development",numberOfPublishedBooks:0,numberOfPublishedChapters:11,numberOfOpenTopics:1,numberOfUpcomingTopics:1,issn:null,doi:"10.5772/intechopen.100360",isOpenForSubmission:!0},{id:"24",title:"Sustainable Development",numberOfPublishedBooks:1,numberOfPublishedChapters:19,numberOfOpenTopics:5,numberOfUpcomingTopics:0,issn:"2753-6580",doi:"10.5772/intechopen.100361",isOpenForSubmission:!0}],subseriesList:[{id:"40",title:"Ecosystems and Biodiversity",scope:"\r\n\tThe environment is subject to severe anthropic effects. Among them are those associated with pollution, resource extraction and overexploitation, loss of biodiversity, soil degradation, disorderly land occupation and planning, and many others. These anthropic effects could potentially be caused by any inadequate management of the environment. However, ecosystems have a resilience that makes them react to disturbances which mitigate the negative effects. It is critical to understand how ecosystems, natural and anthropized, including urban environments, respond to actions that have a negative influence and how they are managed. It is also important to establish when the limits marked by the resilience and the breaking point are achieved and when no return is possible. The main focus for the chapters is to cover the subjects such as understanding how the environment resilience works, the mechanisms involved, and how to manage them in order to improve our interactions with the environment and promote the use of adequate management practices such as those outlined in the United Nations’ Sustainable Development Goals.
",coverUrl:"https://cdn.intechopen.com/series_topics/covers/39.jpg",keywords:"Anthropic Effects, Overexploitation, Biodiversity Loss, Degradation, Inadequate Management, SDGs Adequate Practices"},{id:"38",title:"Pollution",scope:"\r\n\tPollution is caused by a wide variety of human activities and occurs in diverse forms, for example biological, chemical, et cetera. In recent years, significant efforts have been made to ensure that the environment is clean, that rigorous rules are implemented, and old laws are updated to reduce the risks towards humans and ecosystems. However, rapid industrialization and the need for more cultivable sources or habitable lands, for an increasing population, as well as fewer alternatives for waste disposal, make the pollution control tasks more challenging. Therefore, this topic will focus on assessing and managing environmental pollution. It will cover various subjects, including risk assessment due to the pollution of ecosystems, transport and fate of pollutants, restoration or remediation of polluted matrices, and efforts towards sustainable solutions to minimize environmental pollution.
",coverUrl:"https://cdn.intechopen.com/series_topics/covers/38.jpg",keywords:"Human Activity, Pollutants, Reduced Risks, Population Growth, Waste Disposal, Remediation, Clean Environment"},{id:"41",title:"Water Science",scope:"